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A B S T R A C T
Background
Genital infections caused by Chlamydia trachomatis are the most prevalent bacterial sexually transmitted infection worldwide. Screening
of sexually active young adults to detect and treat asymptomatic infectionsmight reduce chlamydia transmission andprevent reproductive
tract morbidity, particularly pelvic inflammatory disease (PID) in women, which can cause tubal infertility and ectopic pregnancy.
Objectives
To assess the effects and safety of chlamydia screening versus standard care on chlamydia transmission and infection complications in
pregnant and non-pregnant women and in men.
Search methods
We searched the Cochrane Sexually Transmitted Infections Group Specialised Register, the Cochrane Central Register of Controlled
Trials (CENTRAL), MEDLINE, EMBASE, LILACS, CINAHL, DARE, PsycINFO and Web of Science electronic databases up to 14
February 2016, together with World Health Organization International Clinical Trials Registry (ICTRP) and ClinicalTrials.gov. We
also handsearched conference proceedings, contacted trial authors and reviewed the reference lists of retrieved studies.
Selection criteria
Randomised controlled trials (RCTs) in adult women (non-pregnant and pregnant) and men comparing a chlamydia screening in-
tervention with usual care and reporting on a primary outcome (C. trachomatis prevalence, PID in women, epididymitis in men or
incidence of preterm delivery). We included non-randomised controlled clinical trials if there were no RCTs for a primary outcome.
Data collection and analysis
Two review authors independently assessed trials for inclusion, extracted data and assessed the risk of bias. We resolved disagreements by
consensus or adjudication by a third reviewer. We described results in forest plots and conducted meta-analysis where appropriate using
a fixed-effect model to estimate risk ratios (RR with 95% confidence intervals, CI) in intervention vs control groups. We conducted a
pre-specified sensitivity analysis of the primary outcome, PID incidence, according to the risks of selection and detection bias.
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Main results
We included six trials involving 359,078 adult women and men. One trial was at low risk of bias in all six specific domains assessed.
Two trials examined the effect of multiple rounds of chlamydia screening on C. trachomatis transmission. A cluster-controlled trial in
women and men in the general population in the Netherlands found no change in chlamydia test positivity after three yearly invitations
(intervention 4.1% vs control 4.3%, RR 0.96, 95% CI 0.84 to 1.09, 1 trial, 317,304 participants at first screening invitation, low
quality evidence). Uptake of the intervention was low (maximum 16%). A cluster-randomised trial in female sex workers in Peru found
a reduction in chlamydia prevalence after four years (adjusted RR 0.72, 95% CI 0.54 to 0.98, 1 trial, 4465 participants, low quality
evidence).
Four RCTs examined the effect of chlamydia screening on PID in women 12 months after a single screening offer. In analysis of four
trials according to the intention-to-treat principle, the risk of PID was lower in women in intervention than control groups, with
little evidence of between-trial heterogeneity (RR 0.68, 95% CI 0.49 to 0.94, I2 7%, 4 trials, 21,686 participants, moderate quality
evidence). In a sensitivity analysis, the estimated effect of chlamydia screening in two RCTs at low risk of detection bias (RR 0.80, 95%
CI 0.55 to 1.17) was compatible with no effect and was lower than in two RCTs at high or unclear risk of detection bias (RR 0.42,
95% CI 0.22 to 0.83).
The risk of epididymitis in men invited for screening, 12 months after a single screening offer, was 20% lower risk for epididymitis
than in those not invited; the confidence interval was wide and compatible with no effect (RR 0.80, 95% CI 0.45 to 1.42, 1 trial,
14,980 participants, very low quality evidence).
We found no RCTs of the effects of chlamydia screening in pregnancy and no trials that measured the harms of chlamydia screening.
Authors’ conclusions
Evidence about the effects of screening on C. trachomatis transmission is of low quality because of directness and risk of bias. There
is moderate quality evidence that detection and treatment of chlamydia infection can reduce the risk of PID in women at individual
level. There is an absence of RCT evidence about the effects of chlamydia screening in pregnancy.
Future RCTs of chlamydia screening interventions should determine the effects of chlamydia screening in pregnancy, of repeated rounds
of screening on the incidence of chlamydia-associated PID and chlamydia reinfection in general and high risk populations.
P L A I N L A N G U A G E S U M M A R Y
Effects of screening for sexually transmitted chlamydia infection
Review question
We reviewed the evidence about the effects ans safety of screening to detect and treat chlamydia infection in women and men.
Background
Chlamydia trachomatis is a common sexually transmitted infection. In several countries, about 3%-5% of sexually active adults aged 15
to 25 years have chlamydia at any given time. Untreated infections can lead to complications, including fertility problems in women
and testicular inflammation in men. Screening to identify and treat people who are unknowingly infected might reduce the risk of
complications and transmission to others.
Study characteristics
The evidence is up to date as of February 2016. We found six trials involving 359,078 adult women and men in Denmark, the
Netherlands, Peru, the UK and the United States. Two trials examined the effect of chlamydia screening on levels of chlamydia infection.
In the Netherlands, investigators invited women and men aged 15 to 29 every year for three years to have a chlamydia test. In Peru,
mobile teams visited 20 cities to offer women sex workers tests for chlamydia over a period of four years.
Key results
With regard to the level of chlamydia infection, in the Netherlands there was no difference in women and men who had been invited
to have yearly chlamydia screening tests compared with women and men who received only one invitation. Only 16% of those invited
to be screened had a test in the first year and only 10% had a test in the third year. In Peru, female sex workers in cities with mobile
teams had lower levels of chlamydia infection than those in cities without mobile teams.
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Four trials provided comparable data on PID. The risk of PID was 32% lower in women who were invited to have a single chlamydia
screening test than in women who were not invited. When we removed two trials with lower quality evidence, the protective effect of
chlamydia screening decreased. I was found no effect on epididymitis in men.
Quality of the evidence
The effect of register-based chlamydia screening on C. trachomatis transmission in young adults in the general population is uncertain.
We are moderately sure that chlamydia screening can reduce the risk of PID, but we are not sure by how much because of our concerns
about quality in some trials.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Chlamydia screening compared with usual care for the prevention of C. trachomatis transmission and reproductive tract morbidity
Patient or population: healthy adults
Settings: general populat ion, high schools or colleges
Intervention: chlamydia screening
Comparison: usual care
Outcomes Absolute effect
(95% CI)
Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Chlamydia prevalence
(general population)
Outcome was chlamydia
test posit ivity af ter 3 yearly
invitat ions in intervent ion
clusters vs 1 invitat ion in
control areas. Uptake was
too low for chlamydia pos-
it ivity to be considered an
unbiased est imate of preva-
lence
RD 0.0% (-0-01, +0.01%) RR 0.96 (0.84 to 1.09) 30,122 (1 study) ⊕⊕©©1,2
Low
Chlamydia prevalence
(high risk population)
Outcome was prevalence
of posit ive chlamydia tests
in repeated cross-sect ional
surveys of women tested at
sex venues af ter 4 years of
intervent ion
RD -3.7% RR 0.72 (0.54 to 0.98) 4156 (1 study) ⊕⊕©©3
Low
Incidence of pelvic inflam-
matory disease (PID) at 12
months (intention- to- treat)
Outcome was clinically di-
agnosed PID reported by
RD 0.0% (0-0, 0.0%) RR 0.68 (0.49 to 0.94) 21,686 (4 studies) ⊕⊕⊕©4
M oderate
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the part icipant or extracted
f rom medical records, phar-
macy records or hospital
discharge coding. Outcome
very likely to be af fected by
risk of detect ion bias
Incidence of epididymitis in
men at 12 months (inten-
tion- to- treat)
Outcome was epididymit is
diagnosed in hospital and
abstracted f rom hospital
discharge coding
RD 0.0% (0.0, 0.0%) RR 0.80 (0.45 to 1.42) 14,980 (1 study) ⊕©©©5,6
Very low
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
CI: conf idence interval; PID: pelvic inf lammatory disease; RR: risk rat io.
1. Select ion, attrit ion and other bias
2. One large non-randomized cluster-controlled trial.
3. Single large trial in female sex workers and uncertainty about generalisability to other screening intervent ions and
populat ions.
4. Select ion bias might have overest imated intervent ion ef fect.
5. Low uptake of the screening intervent ion with an imprecise ef fect est imate and uncertainty about est imated ef fect of
screening intervent ions with higher sustained levels of uptake.
6. Performance bias
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B A C K G R O U N D
Description of the condition
Genital infections caused by Chlamydia trachomatis serovars D-
K are the most prevalent bacterial sexually transmitted infection
worldwide, with an estimated 131 million people being infected
in 2012 (Newman 2015). Chlamydia is the most common no-
tifiable infection in the United States, with 1,441,789 infections
reported in 2014 compared with 350,062 cases of gonorrhoea, the
secondmost commonnotifiable condition (CDC 2015). Chlamy-
dia is also the most commonly reported infection in Australia and
Europe (DoHA 2016; ECDC 2015), and its prevalence is high-
est in young, sexually active adults. The prevalence of chlamydia
has been estimated to be about 3% to 5% in nationally repre-
sentative samples of sexually experienced women and men aged
25 years and under in high-income countries (Redmond 2015).
Chlamydia prevalence in adults aged 15 to 44 years is about 2%
to 3% in low- and lower-middle-income countries, 4% to 7% in
upper-middle countries and 2% to 3% in high-income countries
(Newman 2015).
C. trachomatis is a gram negative obligate intracellular bacterium,
which infects columnar epithelium in the lower genital tract in
women andmen and can also infect the rectum, pharynx, conjunc-
tiva and placenta (Rours 2011; Stamm 2008). Chlamydia infec-
tion causes complications, most commonly due to its spread from
the lower to the upper genital tract. Upper genital tract infection
occurs in both sexes, but is more common and has more severe
consequences in women (Stamm 2008). In women, chlamydia
ascends to the upper genital tract in approximately 10% of cases
to cause symptomatic pelvic inflammatory disease (PID) (Herzog
2012; Oakeshott 2010). The resulting tubal damage can then
cause ectopic pregnancy, tubal infertility and chronic pelvic pain
(Paavonen 2008). Although about 45% of tubal infertility might
be attributable to chlamydia infection (Price 2012), the probability
of tubal infertility in women who have had chlamydia is estimated
to be only 1% to 4% (Kavanagh 2013; Land 2010). Chlamydia
infection in pregnancy is associated with preterm labour and can
infect the neonate, causing ophthalmia neonatorum and atypical
pneumonia (Kohlhoff 2008;Rours 2011).C. trachomatis can cause
epididymo-orchitis in men, but its role in prostatitis and male in-
fertility is not well established (Stamm 2008). Chlamydia can also
cause reactive arthritis in men and is a cofactor for HIV infection,
increasing both susceptibility and infectiousness (Fleming 1999;
Stamm 2008).
Uncomplicated genital chlamydia infections are usually asymp-
tomatic in both women and men (Stamm 2008), and untreated
infections last more than a year on average (Althaus 2010). C. tra-
chomatis can be treated with tetracyclines (usually doxycycline) or
macrolide antibiotics (usually azithromycin) with short-term mi-
crobiological cure rates of 90% to 95% (Manhart 2013). Immu-
nity after chlamydia infection is incomplete, and repeated chlamy-
dia infection is common (Batteiger 2010a). In studies of women
enrolled from primary care and sexual health clinics and followed
up prospectively, about 25% of women treated for chlamydia had
the infection detected again in the year after treatment (Scott
LaMontagne 2007;Walker 2012). There are several reasons for re-
peated detection of chlamydia. In one prospective study amongst
young women in the United States, Batteiger 2010b combined in-
formation about sexual behaviour and genotype from 183 women
with more than one episode of chlamydia infection to estimate
that about 66% of infections were probably acquired from a new
partner, 17% were reinfections from untreated or inadequately
treated sexual partners, 14% were probable antibiotic treatment
failures, and 3% persisted without treatment. There is some evi-
dence to suggest that immunity after natural clearance of chlamy-
dia infection lasts longer than immunity after antibiotic treatment
(Geisler 2013).
Description of the intervention
Screening of sexually active young adults is the only way to detect
most chlamydia infections because of the lack of symptoms or
clinical signs in most infected people. Screening is a process of
identifying apparently healthy people whomay be at increased risk
of a disease or condition. They can then be offered information,
further tests and appropriate treatment to reduce their risk and
the impact of any complications arising from the disease (UKNSC
2013).
There are two goals of screening for genital chlamydia infection:
first, to control the transmission of chlamydia and reduce the
prevalence of infection in the population; and second, to reduce
the risk of complications, especially reproductive tract complica-
tions in women (Meyers 2007; NCSP 2014). Screening is a pro-
gramme, not a test (Raffle 2007). This means that screening in-
cludes the whole system of events needed to reach the endpoint of
reducing the risk of disease or complications. For chlamydia infec-
tion, screening includes offering a test to diagnose C. trachomatis,
treating people with a positive test, partner notification to identify
and treat sexual partners and repeated screening to detect and treat
newly acquired infection or reinfection.
The target group for chlamydia screening is usually defined by age
and sex. For example, recommendations for chlamydia screening
in the United States target women aged 25 years and under (
USPSTF 2014); in Australia, women under 25 (RACGP 2012);
and in the UK, women and men aged 25 years and under (NCSP
2014).Whilst behavioural and demographic factors can be used to
identify groups at higher risk of chlamydia infection, risk factors
differ between populations, and selective criteria can be difficult
to apply in practice (Gotz 2005; Stergachis 1993).
Chlamydia screening can be offered systematically, using a pop-
ulation register to invite people in the target age group (van den
Broek 2012). More commonly, screening is recommended as an
opportunistic activity to be offered to eligible young adults at-
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tending healthcare services (USPSTF 2014;NCSP 2014; RACGP
2012). Some countries recommend repeated screening, given the
frequency of repeated chlamydia and the fact that young adults
may change sexual partners over time (Scott LaMontagne 2007).
In England, the National Chlamydia Screening Programme rec-
ommends a screening test every year or after a change of sex-
ual partner. Health professionals may also take advantage of visits
for cervical cancer screening in young women to offer chlamydia
screening in countries where the target age groups and screening
frequency overlap. In the UK, however, cervical cancer screening
is only recommended for women over 25 years (NCSP 2014).
How the intervention might work
Theway that chlamydia screeningmight work depends on the goal
of screening. To reduce chlamydia prevalence and incidence, the
coverage of screening has to be high enough to identify and treat
prevalent cases of chlamydia and to interrupt chains of chlamy-
dia transmission in the population. Screening also has to be fre-
quent enough to prevent repeated infections because of the lim-
ited immunity after treatment. Mathematical models show that
chlamydia screening reduces prevalence over time; in several mod-
els, screening of 30% or more of the target population each year
is necessary to markedly reduce chlamydia prevalence (Althaus
2012; Regan 2008).
There are two ways in which screening for chlamydia might
work to prevent reproductive tract complications (Herzog 2013;
Peterman 2009). First, direct prevention of PIDoccurs if screening
detects and treats an endocervical chlamydia infection in an indi-
vidual woman before the infection ascends into the genital tract
to cause PID and subsequent tubal damage. The effectiveness of
screening depends on the timing of progression from lower to up-
per genital tract infection. If PID occurs immediately or shortly af-
ter the initial lower genital tract infection, there is no opportunity
for screening to work (Herzog 2012; Smith 2007). Randomised
controlled trials (RCTs) have shown that the incidence of clinically
diagnosed PID is lower in women actively invited for chlamydia
screening compared to those receiving usual care (Andersen 2011;
Ostergaard 2000; Oakeshott 2010; Scholes 2006). Women in-
fected with chlamydia who are enrolled into trials have persisting
prevalent infections with an unknown date of infection. The trial
findings and supportive evidence from mathematical modelling
studies suggest, therefore, that PID development can occur dur-
ing the course of infection (Herzog 2012). Second, prevention of
chlamydia transmission through screening and treatment has an
indirect effect on the risk of PID because it reduces the risk of
becoming infected with chlamydia in the first place.
Preventionof PID should lead to a reduction in the incidence of ec-
topic pregnancy and tubal infertility if tubal scarring is prevented.
It is, however, very difficult to measure the impact of chlamydia
screening on these outcomes because women in the age groups at
highest risk of chlamydia infection are usually using contraception.
In one RCT, the incidence of ectopic pregnancy and infertility af-
ter 11 years of follow-up were similar in women who had received
a single invitation to be screened for chlamydia and women who
received usual care (Andersen 2011).
There are also potential harms of chlamydia screening, for example
an increased rate of repeated infection after treatment or the end-
ing of a sexual partnership (Gottlieb 2011; O’Farrell 2013). First,
a woman who has been treated for chlamydia becomes susceptible
and is at risk of repeated infection and PID. Researchers have sug-
gested that the risk of PID is higher with subsequent chlamydia
infections (Hillis 1997), possibly because repeated exposure to C.
trachomatis antigens can cause immune-mediated tubal damage
(Brunham 2005). Second, being diagnosed with a sexually trans-
mitted infection can have a negative emotional and psychological
impact on the infected person (Gottlieb 2011; Mills 2006). In
one study in the United States, sexual partnerships broke down
for 33% of women with a positive chlamydia test result compared
with 11% of those receiving a negative result (Gottlieb 2011).
Third, the experience of screening can cause anxiety. In a study in
the UK, however, chlamydia screening did not increase anxiety or
depression and did not reduce self esteem (Campbell 2006).
Why it is important to do this review
Screening for chlamydia infection is widely recommended and
practised (USPSTF 2014; Low 2012; NCSP 2014; RACGP
2012). Rates of chlamydia testing amongst young adults are high
(4000 to 9000 per 100,000 population) in several high-income
countries (Bender 2011). There is a strong rationale for early detec-
tion and treatment of chlamydia infection in asymptomatic young
adults to reduce both transmission and complications (Low 2013),
and these potential benefits should be weighed against the poten-
tial harms. There are few data about long-term trends in chlamy-
dia prevalence in countries that recommend chlamydia screening.
In the United States, repeated cross-sectional studies show that
chlamydia prevalence fell between 1999 and 2008 in 14 to 39 year
olds as a whole, but not in 15 to 25 year old women, who are the
target population for screening (Datta 2012).
It is also important to review the effects of screening programmes
from a health policy perspective, as they have implications beyond
the application of a diagnostic test and are costly to administer (
UKNSC2013). Economic evaluations about the cost-effectiveness
of chlamydia screening programmes are not consistent (ECDC
2014).
There is a systematic review of the effectiveness of chlamydia
screening interventions in studies published up to 2007 (Low
2009). RCTs have found that a one-off screening invitation could
reduce the incidence of PID one year later (Ostergaard 2000;
Scholes 1996). Also, we know that there are new completed tri-
als with PID and transmission as endpoints (Andersen 2011;
Oakeshott 2010; van den Broek 2012), and there is at least one
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ongoing trial (Hocking 2012). It is therefore important to develop
a Cochrane review about this issue.
O B J E C T I V E S
To assess the effects and safety of chlamydia screening versus stan-
dard care for chlamydia transmission and infection complications
in pregnant and non-pregnant women and in men.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised and non-randomised controlled trials.
We included controlled trials with non-randomised allocation to
intervention and control arms if there were no RCTs addressing a
primary outcome of chlamydia screening.
We included trials with cluster allocation as long as investigators
collected baseline and outcome data prospectively using the same
criteria throughout the trial period.
We analysed results from randomised and non-randomised study
designs separately.
We excluded cohort studies, case-control studies and interrupted
time-series studies.
Types of participants
We included women (non-pregnant and pregnant) and men (het-
erosexual or men who have sex with men) aged over 13 years in
any setting. The minimum age was arbitrary but allowed us to
include only trials of sexually transmitted chlamydia infections.
Types of interventions
• Intervention: screening for sexually transmitted genital
chlamydia infection, defined as the offer of a test to apparently
healthy people to identify those at increased risk of chlamydia
infection. This definition was adapted from the UK National
Screening Committee (UKNSC 2013). We included any test
used to diagnose genital chlamydia infection.
• Comparison: inactive control (no offer of screening or
standard care)
Types of outcome measures
Eligible trials included at least one of the pre-specified primary
outcomes. The primary outcomes were measures of morbidity
because one criterion for assessing the effectiveness of a screen-
ing programme is that ’there should be evidence from high
quality Randomised Controlled Trials that the screening pro-
gramme is effective in reducing mortality or morbidity’ (http://
www.screening.nhs.uk/criteria).
Primary outcomes
We included one primary outcome for each goal of chlamydia
screening.
• Outcome for C. trachomatis transmission: prevalence of
chlamydia infection in women and men at least 12 months after
the start of the screening intervention. Prevalence was estimated
as the number of positive chlamydia tests divided by the number
of people tested.
• Outcomes for reproductive tract morbidity: incidence of
upper genital tract infection in women and men in the 12
months after the offer of screening. PID (women) or
epididymitis (men) were clinical diagnoses made using clinical
criteria defined in advance by the authors. Examples include
criteria published by USPSTF 2014 or Hager 1983.
• Outcome for chlamydia infection in pregnancy: incidence
of preterm delivery. Preterm delivery was defined as delivery at a
gestational age of less than 37 weeks, with subgroups of
gestational ages less than 32 weeks and less than 35 weeks (Rours
2011).
Secondary outcomes
• Outcomes measured in all participants
◦ Proportion of participants receiving the intervention,
defined as the number tested for chlamydia divided by the
number eligible and invited to take part. We did not consider
uptake of chlamydia testing as a primary outcome because it is
an intermediate outcome of a chlamydia screening intervention,
and the relationship between uptake of screening and the
primary outcomes has not been quantified.
◦ Harms of screening, including psychological distress,
partner violence, relationship breakdown, using definitions
described by the authors
• Outcomes measured in women who were not pregnant
during the trial or in men
◦ Prevalence of chronic female pelvic pain, defined as
patient-reported pain in the lower abdomen or pelvis lasting at
least six months (Paavonen 2008)
◦ Prevalence of female or male infertility, defined using a
clinical definition of lack of pregnancy despite unprotected
intercourse for 12 months or more (Paavonen 2008)
• Outcomes measured in women who were pregnant during
the trial, or in their infants
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◦ Incidence of C. trachomatis neonatal conjunctivitis,
defined as C. trachomatis isolated from the conjunctiva by culture
or detected by nucleic acid amplification test (Kohlhoff 2008)
◦ Incidence of C. trachomatis neonatal pneumonitis,
defined as signs of lower respiratory tract infection presenting
between 4 and 12 weeks with C. trachomatis isolated from the
nasopharynx by culture or detected by nucleic acid amplification
test (Kohlhoff 2008)
Search methods for identification of studies
We aimed to identify trials meeting the inclusion criteria irrespec-
tive of their language, publication date or publication status (pub-
lished, unpublished, in press and in progress). We used both elec-
tronic searching in bibliographic databases and handsearching, as
described in the Cochrane Handbook for Systematic Reviews of In-
terventions (Higgins 2011a).
We downloaded and managed the results of all searches using
Endnote bibliographic software. We deleted duplicate records of
the same study.
Electronic searches
The Cochrane Sexually Transmitted Infections (STI) Review
Group Specialised Register includes RCTs and controlled clinical
trials, from 1944 to 2015, located through electronic searching in
the Cochrane Central Register of Controlled Trials (CENTRAL),
MEDLINE and EMBASE, and handsearching in journals not in-
dexed in those databases (according to the journals’ master list of
the STI Cochrane Review Group): Anatolian Journal of Obstetrics
& Gynecology, Current Medical Literature Gynecology & Obstetrics,
Current Obstetrics and Gynecology Reports, ISRNObstetrics and Gy-
necology, Journal of South Asian Federation of Obstetrics & Gynecol-
ogy,Obstetrics and Gynecology International,Obstetrics Gynaecology
and Reproductive Medicine, and Sexual Science: the newsletter of the
Society for the Scientific Study of Sexuality and Sexualities.
The Trials Search Coordinator (TSC) of the STI Cochrane Re-
view Group implemented a comprehensive search strategy to cap-
ture as many relevant trials as possible in electronic databases.
We used a combination of controlled vocabulary (MeSH, Emtree,
DeCS, including exploded terms) and free-text terms (considering
spelling variants, plurals, synonyms, acronyms and abbreviations)
for ’genital chlamydia infection’ and ’screening’, with field labels,
truncation, and proximity and Boolean operators. We present the
electronic search strategies in Appendix 1.
We searched the following electronic databases.
• The Cochrane Sexually Transmitted Infections (STI)
Review Group Specialised Register.
• CENTRAL, Ovid platform.
• MEDLINE, Ovid platform (1991 to February 2016).
• MEDLINE In-Process & Other Non-Indexed Citations,
Ovid platform (January 1946 to February 2016).
• MEDLINE Daily Update, Ovid platform (January 1946 to
February 2016).
• EMBASE (1947 to February 2016).
• LILACS, iAHx interface (1982 to February 2016).
• CINAHL (inception to February 2016).
• Database of Abstracts of Reviews of Effects (DARE)
(inception to February 2016).
• PsycINFO (inception to February 2016).
We searched MEDLINE using the Cochrane highly sensitive
search strategy for identifyingRCTs: sensitivity and precisionmax-
imizing version (2008 revision), Ovid format (Higgins 2011a).
We combined the LILACS search strategy with the RCT filter of
the iAHx interface.
Searching other resources
1. Trial registers
i) WHO International Clinical Trials Registry Platform
(ICTRP) portal (http://apps.who.int/trialsearch/) (inception to
February 2016)
ii) ClinicalTrials.gov (http://clinicaltrials.gov/) (inception
to February 2016)
2. Web of Science (inception to February 2016)
3. Grey literature in System for Information on Grey
Literature in Europe ’OpenGrey’ (http://www.opengrey.eu/)
(inception to February 2016)
4. Handsearch of conference proceeding abstracts
i) The International Society for Sexually Transmitted
Diseases Research - ISSTDR (http://www.isstdr.org/): 2007,
2009 and 2011
ii) The British Association for Sexual Health and HIV -
BASHH (http://www.bashh.org/): 2004, 2006, 2007 and 2009
iii) International Congress on Infectious Diseases - ICID (
http://www.isid.org/): 2010 and 2012
iv) The International Union against Sexually Transmitted
Infections - IUSTI (http://www.iusti.org/): 2011 and 2012
v) International Society for Infectious Diseases - ISID (
http://www.isid.org/): 2011
vi) International Meeting on Emerging Diseases and
Surveillance - IMED (http://www.isid.org/): 2007, 2009 and
2011
vii) Interscience Conference on Antimicrobial Agents and
Chemotherapy - ICAAC (http://www.icaac.org/): 2011 and
2012
viii) The International Federation of Gynecology and
Obstetrics - FIGO (http://www.figo2012.org/home/): 2012
5. Handsearching previous systematic reviews and other
relevant publications on the same topic
6. Handsearching reference lists of all relevant RCTs identified
by other methods
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Data collection and analysis
Selection of studies
Two review authors (NL, SR) independently reviewed titles and
abstracts of articles identified through the search strategy, using a
pilot-tested form to document potential eligibility. We obtained
the full-text records that both review authors agreed were poten-
tially eligible as well as articles about which the authors still dis-
agreed after discussion; we also retrieved records with no abstract
if there was insufficient information available from the title or
publication type to make a decision.
We used the same criteria for the abstracts of articles identified
through searching other resources as for studies identified through
electronic database searches.
NL and SR examined full-text records using a pilot-tested form to
assess eligibility, andwe included studies identified by both authors
as fulfilling our inclusion criteria. Where there were discrepancies,
the authors discussed the article and reached a consensus decision.
We used a flow chart to document the numbers of articles assessed,
included and excluded at each stage, with a summary of reasons
for exclusion (Figure 1). The flow chart shows the total number
of studies included in the review and the total number of articles
pertaining to these studies. We briefly record the characteristics of
excluded studies in case readers might expect them to have been
included.
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Figure 1. #Study flow diagram.
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Data extraction and management
We used piloted, standardised forms to extract data about:
• study location and setting;
• trial design and power calculation;
• ethical approval;
• inclusion and exclusion criteria;
• baseline characteristics of trial participants, including sex,
age, sexual orientation, pregnancy status for women, diagnostic
test used to detect C. trachomatis;
• types of intervention: opportunistic or systematic invitation
for screening, number of screening rounds, screening interval;
• types of comparison group: usual care, alternative screening
method;
• types of outcome: primary, secondary;
• reporting of methodological characteristics (see next
section, Assessment of risk of bias in included studies for details).
We extracted numerical data on:
• number of people assessed for eligibility;
• numbers randomised to intervention and comparison
groups;
• numbers receiving screening in intervention and
comparison groups (at each screening round if multiple rounds);
• numbers included in analyses in intervention and
comparison groups;
• numbers with outcomes in intervention and comparison
groups;
SR extracted data about study characteristics, and NL checked
these details for accuracy. They resolved discrepancies by discus-
sion.
Pairs of appropriately qualified review authors (BA and JvB, HG
and NL, AU and HW) extracted numerical data independently
from each included study into Epidata using a structured form
(Epidata). If a reviewer had been an investigator of an included
study, they did not extract data from that study. If there were
multiple publications relating to the same study, we allowed the
extraction of data items from different publications. If there were
discrepancies between publications about a data item, we used
the data presented in the main trial publication (the publication
that includes the results for the primary outcome) or the first
chronological publication reporting that data item.
We compared the two files using the validation function available
in Epidata, resolving discrepancies in data extraction or data entry
by consensus. If there was no agreement, a third independent
author adjudicated tomake a final decision. We entered the agreed
data into Review Manager 5.3 (RevMan) software (RevMan).
If there were insufficient details given to allow the extraction of
numerical data, we included the study and described the results
narratively.
Assessment of risk of bias in included studies
We assessed the methods that trial authors reported using in the
design and execution of all included trials. The assessment deter-
mined whether there was a risk of bias that would over- or under-
estimate the effect of the intervention on one or more outcomes
(Higgins 2011a). This assessment relied on reports of methods
described by trial authors in publications and, where available,
trial protocols. For any trial, the findings of the assessment could
only say whether there was a risk of biased results, not whether the
results themselves were or were not biased.
For both randomised and non-randomised trials, we assessed the
risk of five specific sources of bias: selection bias, performance
bias, detection bias, attrition bias and reporting bias, and we also
recorded any other biases related to a particular trial.
For RCTs we used the Cochrane ’Risk of bias’ tool and criteria in
Higgins 2011a (Table 8.5.d) to assess the relevant domains of the
reported methods and results (Reeves 2011).
Selection bias was only the domain for which there are important
differences in assessing the risk of bias in randomised and non-
randomised controlled trials. For non-randomised controlled tri-
als, we used the UK National Insitute of Health and Care Excel-
lence (NICE) ’methodology checklist’ for cohort studies to assess
the risk of selection bias (NICE 2012). The NICE methodology
checklist format follows that of the Cochrane tool, with criteria to
assess bias in each domain and a choice of low, high or unclear risk
of bias. We used the Cochrane ’Risk of bias’ tool to assess non-
randomised controlled trials for risk of performance, detection,
attrition and reporting biases.
Assessors recorded whether there was a low, high or unclear risk of
bias in each domain of each included trial and gave a justification
for their decision. Two independent assessors assessed each trial,
including at least one expert in trial methodology (NL) and one
expert in chlamydia screening (HG). They resolved discrepancies
by discussion.
The domains and their source are summarised here.
(1a) Random sequence generation (possible selection bias,
Cochrane ’Risk of bias’ tool)
Selection bias could occur if investigators are able to predict alloca-
tion to intervention or control groups and selectively enrol partic-
ipants or clusters of participants. The method used to generate the
allocation sequence should be unpredictable and should balance
prognostic factors, on average, across intervention and compari-
son groups. We assessed the method as being at:
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• low risk of bias (adequate description of a truly random
process, e.g. random number tables, computer-generated
random numbers);
• high risk of bias (explicit description of an allocation
process that is not truly random, e.g. odd or even dates of birth
of individuals, clusters of participants selected for
implementation of the intervention with subsequent enrolment
of comparison groups); or
• unclear risk of bias (description that does not include
enough information to decide whether sequence generation was
truly random or not).
(1b) Allocation concealment (possible selection bias,
Cochrane ’Risk of bias’ tool)
Selection bias can occur if investigators selectively enrol partici-
pants or clusters of participants and allocate them to a particular
group according towhether their characteristics are associatedwith
the outcome. If the sequence has been randomly generated, selec-
tive enrolment can occur if the next assignment is known before
allocation. Allocation concealment up to the point of assignment
prevents selective assignment to a particular intervention group.
We assessed the methods of allocation concealment as having:
• low risk of bias (adequate description of a process that
prevented foreknowledge of allocation up to the point at which
assignment was recorded, e.g. telephone or central
randomisation);
• high risk of bias (description of a process that meant that
those assigning participants or clusters of participants knew or
could predict the allocation in advance); or
• unclear risk of bias (insufficient details to be able to decide
whether the allocation was concealed or not).
(1c) Systematic differences between comparison groups
(possible selection bias, NICE ’methodology checklist’)
In a non-randomised trial, selection bias can occur because of
the lack of a random allocation sequence and concealment. If the
person assigning individuals or clusters to a particular group knows
about the distribution of factors associated with the outcome, they
might introduce selection bias. We assessed studies as having:
• low risk of bias (the reason for participant allocation to
treatment groups is not expected to affect the outcomes of the
study, there were attempts made within the design or analysis to
balance the comparison groups for potential confounders, and
the groups were comparable at baseline for all known major
confounders and prognostic factors);
• high risk of bias (any of the above conditions are not
fulfilled); or
• unclear risk of bias (insufficient details to be able to decide
whether there was a risk of systematic differences between
comparison groups).
(2) Blinding of participants and personnel (possible
performance bias)
Screening is an intervention that involves systematic differences
in the delivery of a health service. Personnel who offer chlamydia
screening tests might offer other sexual health information, advice
or interventions, such as condoms, that could affect participants’
risk of chlamydia infection or another outcome. Such information
and interventions could also be considered a part of the screening
programme, however. Trial participants or clusters of participants
in an inactive ’usual care’ control group might also be considered
blinded if they do not know that they are part of a trial. For
each included trial, we described the intervention. We considered
studies as being at low risk of bias if participants were blinded or
if the lack of blinding was unlikely to affect results for a particular
outcome.
(3) Blinding of outcome assessment (possible detection bias)
For chlamydia screening interventions, adequate descriptions of
blinding of those assessing the outcomes are important. We dis-
tinguished between outcomes that were objectively assessed (e.g.
chlamydia test results obtained from automated diagnostic sys-
tems) and those that were subjective (e.g. clinical diagnosis of
pelvic inflammatory disease).
The incidence of clinically diagnosed pelvic inflammatory disease
is a primary outcome of chlamydia screening interventions. The
main symptom is lower abdominal pain, which is common and
non-specific. Knowledge of group assignment could influence the
interpretation of symptoms by both trial participants and person-
nel delivering the intervention in unpredictable ways. For exam-
ple, healthcare providers who know whether a woman has been
screened for chlamydia might be more likely to assign a diagno-
sis of pelvic inflammatory disease to a woman who presents with
abdominal pain because of increased awareness of the complica-
tions of chlamydia infection. On the other hand, they might be
reassured if the test was negative or if treatment had been given
and then interpret abdominal pain with or without accompanying
signs as resulting from another cause. Women who have accepted
or declined screening might also modify their assessment of symp-
toms or their health-seeking behaviour. For subjective outcomes,
we assessed methods as having:
• low risk of bias (adequate description of assessment that
reduced the risk of bias, e.g. uniform assessment of all trial
participants by an independent assessor blinded to allocation, or
assessment of diagnoses by an independent assessment panel
blinded to allocation);
• high risk of bias (assessment of outcomes by personnel who
knew the group assignment); or
• unclear risk of bias (insufficient information to determine
whether outcome assessment was blinded or not).
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(4) Incomplete outcome data (possible attrition bias due to
the amount, nature and handling of incomplete outcome
data)
For each outcome or class of outcomes, we described the complete-
ness of data and exclusions from analysis in each included trial.We
stated whether analyses were conducted and reported according
to intention-to-treat or not. Where reported, we stated numbers
included in the analysis as a proportion of the totals randomised
to intervention and comparison groups, reasons for attrition or
exclusion, and whether missing data were balanced across groups
or were related to outcomes. Where trials or trial authors provided
sufficient information, we re-included missing data in our analy-
ses. We used a cutoff of 20% to assign trials with missing outcome
data as being at low or high risk of bias. In addition, we assessed
methods as being at:
• low risk of bias (e.g. no missing outcome data; missing
outcome data balanced across groups);
• high risk of bias (e.g. numbers or reasons for missing data
imbalanced across groups; ’per protocol’ analysis done with
substantial departure of intervention received from that assigned
at randomisation); or
• unclear risk of bias (insufficient information about missing
data or exclusions from analysis).
(5) Selective outcome reporting (possible reporting bias)
Where available, we assessed the trial protocol and trial registration
documents as well as articles or publications resulting from a trial.
We described the documents available for each included study and
assessed the methods as having:
• low risk of bias (adequate description that reports all pre-
specified outcomes and all expected outcomes of interest to the
review);
• high risk of bias (explicit evidence that trials did not report
all pre-specified outcomes or did not pre-specify one or more
reported primary outcomes, that they reported outcomes of
interest incompletely so that they cannot be used in the review,
or that there are no results for a key outcome that would have
been expected to have been reported); or
• unclear risk of bias (insufficient information to decide
whether selective reporting bias is likely or not).
(6) Other biases
For each included trial we described other potential sources of
bias. We assessed these sources after data extraction and did not
pre-specify them in the protocol.
We assessed trials that received any funding from pharmaceutical
or diagnostic manufacturers as being at unclear risk of bias.
’Contamination’ of the intervention could occur if chlamydia test-
ing in the control group increased to approach the levels achieved
in the intervention group. This would reduce the size of the ef-
fect in cluster-randomised trials. Contamination could also occur
in a cluster-controlled trial if sexual mixing between individuals
in intervention and control groups occurred. We assessed trials as
being at:
• low risk of bias (adequate description that contamination
did not occur or was not relevant to the trial design);
• high risk of bias (explicit evidence that contamination
occurred, with documentation of chlamydia testing rates in
control group during the intervention period); or
• unclear risk of bias (contamination was possible but there
was insufficient information to assess).
Measures of treatment effect
We compared the treatment effect or harmful effect for each out-
come in the intervention versus the control group, expressing the
association as a risk ratio (RR) with 95% confidence intervals (CI).
An advantage of the RR is that it can be interpreted easily for both
high and low event rates. We also calculated the risk difference
(RD, 95% CI), the actual difference in the event rate between
intervention and control groups.
For the primary outcome of chlamydia prevalence, we reported
the overall effect estimate at the level of the cluster, and stated
whether the analysis took into account the correlation between
individuals within a cluster.
Unit of analysis issues
Cluster-randomised trials of chlamydia screening interventions
might measure the effect of the intervention in a geographic area
or a school community. In trials of chlamydia screening, the inter-
vention affects not only individuals who are screened and treated
(direct effect), but their sexual partners and members of the same
sexual network (indirect effect). The indirect effect of screening
can reduce the level of repeated exposure to infection of individ-
uals within a cluster.
Ifmeta-analysis was appropriate and both individually and cluster-
randomised trials reported the same outcome, we adjusted the size
of the trial to an ’effective sample size’ (Campbell 2005; Higgins
2011a; Ukoumunne 1999). We then combined the effect sizes
in meta-analyses. The effective sample size took into account the
design effect of the cluster, based on the average cluster size and
intraclass correlation coefficient (ICC). The design effect was (1 +
(average cluster size - 1) * ICC). We calculated an effective sample
size, dividing both number of events and number of participants
by the design effect (Higgins 2011a).
This issue applied to the outcome PID in (Ostergaard 2000),
which had 17 clusters (schools) and an average cluster size of 100.
The trial publication did not report the ICC sowe used an external
source that reported a median ICC of 0.028 for 12-month follow-
up data from cluster-randomised trials of adolescent HIV/STI/
pregnancy prevention interventions (Glassman 2015). The design
effects were 3.77 for the intention-to-treat and 2.5 for per protocol
data.
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If we identified studieswithmultiple treatment groupswe reported
all intervention groups in the ’Characteristics of included studies’
section and included only those that met the inclusion criteria.
We combined relevant groups to create a single pair-wise compar-
ison; all relevant intervention groups were combined into a single
intervention group.
Dealing with missing data
We reported the percentage of observations with missing data in
each included trial. We used sensitivity analyses to explore the
effect of including or excluding trials with > 20% missing data.
For each outcome we attempted to analyse data according to the
intention-to-treat principle, with all participants included in the
group to which they were randomised and exclusion only of par-
ticipants with missing outcome data.
Assessment of heterogeneity
We reported statistical heterogeneity in results between studies us-
ing I2, Tau2 andChi2 statistics obtained from analyses in RevMan.
We used the I2 statistic to quantify the percentage of variability
between the results that is due to heterogeneity rather than sam-
pling error (Higgins 2002). We took into account the fact that I
2 values are affected by the number of studies, the magnitude and
direction of effects in individual trials, and the strength of evidence
of heterogeneity. In general, we considered I2 values below 40%
as showing little evidence of statistical heterogeneity.
Assessment of reporting biases
We looked for evidence of publication and other reporting biases
using funnel plots that plot the effect size against precision. If there
were more than 10 studies in a meta-analysis we used statistical
tests of funnel plot asymmetry for continuous or binary endpoints
(Egger 1997; Harbord 2005).
Data synthesis
We described the results of trials where there were too few studies
for meta-analysis or where we considered that meta-analysis was
not clinically meaningful. We used forest plots to display results
of trials examining the same outcome.
Where appropriate, we combined data using meta-analyses con-
ducted in RevMan. If there were trials that examined the same
intervention and measured the same underlying effect in similar
populations, we used a fixed-effect model. If there was clinical
heterogeneity or evidence of substantial statistical heterogeneity,
we used a random-effects model to estimate the average treatment
effect across trials. We presented results as the summary RR (95%
CI) with I2 and Tau2 estimates. For meta-analyses with at least
three studies combined using a random-effects model, we also cal-
culated a prediction interval to examine the range of effect esti-
mates that might be expected in different settings or populations
(Riley 2011). We did not combine results from randomised and
non-randomised trials in the same meta-analysis but compared
these in a sensitivity analysis.
Subgroup analysis and investigation of heterogeneity
If there was evidence of substantial heterogeneity (I2 greater than
40%) for the primary outcome measures and if there were enough
trials, we used subgroup analyses to explore it. We explored the
following subgroups.
• Sex of the participant.
• Level of sexual behaviour risk of the study population (high
risk, low risk).
• Uptake of the intervention (greater or less than 50%).
• Intensity of the intervention (single offer, multiple
screening rounds).
For fixed-effectmodels based on inverse variancemeta-analysis, we
used tests of interaction to examine differences between groups.
For random-effects models and fixed-effect models using methods
other than inverse variance, we inspected confidence intervals for
the subgroup estimates.
Sensitivity analysis
We planned to conduct the following sensitivity analyses to inves-
tigate the influence of methodological aspects of the review that
might influence the results.
1. The treatment effect for pelvic inflammatory disease
incidence in RCTs assessed as being at low versus high risk of
detection bias (i.e. blinded versus non-blinded assessment).
2. The treatment effect for each primary outcome in RCTs
assessed at being at low versus high risk of selection bias.
3. The treatment effect for chlamydia prevalence in RCTs
versus non-randomised studies.
4. The treatment effect for each primary outcome in
intention-to-treat versus per protocol study populations.
In view of the small number of included studies, we only did
sensitivity analyses for PID as an outcome.
Summary of findings table
We produced a ’Summary of findings’ table to present the assess-
ment of the overall level of evidence for each primary outcome
(Higgins 2011b).We used the GRADE approach, as incorporated
in RevMan. We summarised the quality of evidence as high, mod-
erate, low or very low. We downgraded the overall level from ’high
quality’ by one level for serious (and by two levels for very serious)
methodological limitations (risk of bias), inconsistency of results,
indirectness of evidence, imprecision or publication bias.
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R E S U L T S
Description of studies
Results of the search
Our search strategy identified 981unique records as of 14February
2016 (Figure 1).Of these, we examined the full textmanuscript for
150 records. We found 10 potentially eligible trials (33 records).
Of these, fourwere ongoing trialswith no results about the primary
outcomes (Characteristics of ongoing studies) (Hocking 2010;
Kaldor 2010; Lehtinen 2015; NCT01195220).
Included studies
We included six trials that studied 359,078 adultwomen andmen (
Characteristics of included studies). Scholes 1996 took place in the
United States, Andersen 2011 and Ostergaard 2000 in Denmark,
Oakeshott 2010 in theUK, vandenBroek 2012 in theNetherlands
and Garcia 2012 in Peru.
Participants
Two trials included both women and men. Andersen 2011 en-
rolled 30,439 women and men aged 21 to 23 years, selected at
random from the county health service register in Aarhus, Den-
mark. van den Broek 2012 took place in three locations in the
Netherlands; investigators invited all women and men aged 16
to 29 years in Amsterdam and Rotterdam, while in South Lim-
burg, participants were women and men aged 16 to 29 years who
completed a web-based questionnaire and had a score indicating a
high risk of chlamydia infection (total 317,304). Ostergaard 2000
enrolled both women and men, but for this review, primary out-
come data were only from 1700 women aged around 18 years in
high schools in Aarhus. Three trials included only women (Garcia
2012; Oakeshott 2010; Scholes 2007, total 9635).
Four trials enrolled participants from the general population,
rather than from groups known to be at high risk of chlamydia
infection (Andersen 2011; Oakeshott 2010; Ostergaard 2000; van
den Broek 2012). Andersen 2011 and van den Broek 2012 in-
vited people from municipal population registers so the eligible
participants in these trials could be considered representative of
the general population. Ostergaard 2000 invited students in their
final year at school. The trial included all schools in one Danish
county, so the eligible participants would be representative of the
general population. Oakeshott 2010 invited older students at fur-
ther education colleges in London and only enrolled those agree-
ing to be tested for chlamydia.
Two trials enrolled participants at increased risk of chlamydia.
Scholes 1996 randomised 36,547 women aged 18 to 34 years in
a health maintenance organisation in the United States, assessed
questionnaire responses from 20,836 and enrolled 2607 who had
a score indicating a high risk of chlamydia infection and agreed to
take part. Garcia 2012 implemented an intervention for female sex
workers (median age 22 years, interquartile range 20 to 26 years)
in 20 cities in Peru and assessed 4465 in repeated cross-sectional
surveys.
Trial design
In two RCTs, individuals were first randomised to interven-
tion and control groups and then invited to undergo screening
(Andersen 2011; Scholes 1996). In Andersen 2011, individuals in
the intervention group were selected at random from the popula-
tion register and then invited by post to undergo screening. In the
trial by Scholes 1996, women in the intervention group fulfilling
criteria for being at high risk of chlamydia were invited to a study
clinic. In both control groups, individuals could receive usual care
but did not receive any further information about the trial.
In one RCT, Oakeshott 2010 invited women to take part and ran-
domised those who agreed to be tested for chlamydia individually
to intervention or control groups.
The other three trials used a cluster design (Garcia 2012;
Ostergaard 2000; van den Broek 2012). In the RCTs by Garcia
2012 and Ostergaard 2000, the clusters were allocated to inter-
vention or control groups, and investigators compared outcomes
at the same time points in both groups. In Ostergaard 2000 the
statistical analysis did not account for clustering.
van den Broek 2012 used a stepped wedge design in a controlled
clinical trial. Clusters were postal areas, which were allocated to
intervention (two groups of postal areas) and control areas (one
group of postal areas) according to population size, level of com-
munity risk of STI (low, medium or high) and demographic char-
acteristics (proportions of 16 to 29 year olds, African Caribbean
minority ethnic groups and low income earners). The screening
intervention was rolled out sequentially in a randomly determined
order so that each person in the cluster received an invitation for
screening at least once. People in the intervention group clusters
received three invitations at roughly 10-month intervals. The con-
trol group clusters received only one screening invitation. We in-
cluded this trial because there were no RCTs in the general popula-
tion that reported prevalence of chlamydia as a primary outcome.
For the outcome of PID, we estimated the design effect for partic-
ipants in 164 clusters involved in the first two screening rounds.
Screening interventions
Four trials used a register-based approach to identify and invite po-
tentially eligible participants (Andersen 2011; Ostergaard 2000;
Scholes 1996; van den Broek 2012). In Ostergaard 2000, the reg-
ister included the final classes of high schools, and students in the
intervention group received an invitation to be screened by means
of a home-collected specimen. Two trials identified participants
from municipal population registers and sent a postal invitation
16Screening for genital chlamydia infection (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
that offered a screening test by means of a home-collected speci-
men (Andersen 2011; van den Broek 2012). Andersen 2011 tested
two methods for offering the home-collected specimen. We com-
bined the results for both methods into a single intervention. All
four trials used nucleic acid amplification tests to detect C. tra-
chomatis.
In the trial by Scholes 1996, women in the intervention group
were invited to a study clinic to have endocervical swabs taken
by a physician. C. trachomatis was detected by enzyme-linked im-
munoassay.
Two trials used a venue-based approach. In the trial by Oakeshott
2010, women were approached in colleges. All women gave con-
sent to be screened before enrolment. They provided a self col-
lected vaginal swab specimen. Those in the intervention group
received their results and were treated if the chlamydia test result
was positive. Women in the control group had their specimens
stored and received the result one year later. They were therefore
unscreened for one year and underwent deferred screening. Garcia
2012 used mobile teams who visited sex work venues of 8-week
periods in each city. They invited female sex workers opportunis-
tically and offered testing for chlamydia and other STIs. C. tra-
chomatis was detected by nucleic acid amplification test.
All trials made arrangements to follow up and treat participants
with positive screening test results. Two trials offered screening on
more than one occasion (Garcia 2012; van den Broek 2012).
Primary outcomes
Outcome for C. trachomatis transmission
Three trials measured the proportion of positive chlamydia test
results amongst all screened participants in women (in the case of
Garcia 2012) or in women and men (in Ostergaard 2000 and van
den Broek 2012) at least 12 months after the start of the screening
intervention. Garcia 2012 measured the prevalence of positive test
results among samples of female sex workers at sex work venues in
each city in 2002 and 2003 (baseline) and at follow-up in 2005
and 2006, after implementing the intervention. van den Broek
2012 measured the prevalence of positive chlamydia test results
following each round of postal invitations. They compared the re-
sults in postal areas that had received two or three yearly invitations
versus those that had received only one invitation (control group).
Ostergaard 2000 measured chlamydia prevalence amongst women
who agreed to be followed up 12 months after the intervention,
but there was no measure of prevalence in the control group at
baseline (Table 1).
Outcomes for reproductive tract morbidity
Five trials measured the incidence of PID in women in the 12
months after the offer of screening (Andersen 2011; Oakeshott
2010; Ostergaard 2000; Scholes 1996; van den Broek 2012). For
the cluster-randomised trial by Ostergaard 2000, we applied a
design effect of 3.77 (based on an ICC 0f 0.028) to calculate an
effective sample size so that we could combine the results with
those of the individually randomised trials (Glassman 2015).
One trial measured the incidence of epididymitis in men in the
12 months after the offer of screening (Andersen 2011).
Outcome for chlamydia infection in pregnancy
We did not find any RCTs that measured the incidence of preterm
delivery or secondary outcomes related to chlamydia screening in
pregnancy.
Secondary outcomes
Outcomes measured in all participants
• Proportion of participants receiving the intervention
(screening uptake) (Andersen 2011; van den Broek 2012)
• Harms of screening (not reported in any trial)
Outcomes measured in women who were not pregnant
during the trial or in men
• Prevalence of chronic female pelvic pain (not reported in
any trial)
• Prevalence of female infertility and incidence of ectopic
pregnancy (Andersen 2011)
• Male infertility (not reported in any trial)
We did not find any trials reporting neonatal outcomes of chlamy-
dia screening interventions.
Excluded studies
We assessed and excluded 41 full-text records. Of these, 31 were
RCTs that involved screening for chlamydia but did not report a
pre-specified primary outcome (ISRCTN38526137; Bailey 2013;
ISRCTN16261241; Bowden 2008; Brown 2010; Chandeying
1998; Cook 2007; De Barbeyrac 2013; Downing 2013; Gotz
2013; Graseck 2010; Guy 2013; ACTRN12608000499381;
Jones 2007; Kersaudy-Rahib 2013; Klovstad 2013; Lawton 2010;
McKee 2011; Meyer 1991; Niza 2014; NCT01654991; Scholes
2006; Scholes 2007; NCT00829517; Senok 2005; Shafer 2002;
Smith 2014; Tebb 2005; Tebb 2009; Walker 2010; Xu 2011).
We excluded two trials that reported chlamydia prevalence as an
outcome. One was a non-randomised controlled trial with retro-
spective inclusion of a control group (Cohen 1999). One trial did
not measure chlamydia prevalence in all eligible participants in the
control group (Hodgins 2002). We assessed and excluded eight
studies in pregnant women (Andrews 2006; Banhidy 2011; Kekki
2001; Kiss 2004;Martin 1997;McGregor 1990;McGregor 1995;
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Stevens-Simon 2002). None involved chlamydia screening as the
intervention.
Risk of bias in included studies
Of the six included trials, we considered one to be at low risk of
bias in the six specified domains (Garcia 2012). The other trials
had an unclear or high risk of bias in at least one domain (Figure
2; Figure 3).
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Figure 3. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
Allocation
Of the five RCTs, four were at low risk of selection bias in the
generation of the randomisation sequence. Two used computer-
generated lists (Andersen 2011; Garcia 2012), one used random
number tables (Oakeshott 2010), and one allocated schools by
drawing lots from a hat (Ostergaard 2000). In one RCT the risk
of bias was unclear because the methods only stated that “women
were randomly assigned” (Scholes 1996).
In van den Broek 2012, allocation to intervention and control
groups did not follow a randomly generated sequence, so we
judged it to be at high risk of bias in this domain.
We judged two trials to be at low risk of bias for allocation con-
cealment, as they explicitly stated that neither participants nor
staff could predict the allocation (Garcia 2012; Oakeshott 2010).
Andersen 2011 did not explicitly describe allocation concealment,
but we judged it to be at low risk of bias, as individuals in the
intervention group were selected at random from a population
register and invited to be screened without knowing that there was
a control group.
Unconcealed allocation resulted in a high risk of selection bias in
two trials in which randomisation occurred before seeking con-
sent (Ostergaard 2000; Scholes 1996). In both trials the ratio
of intervention to control group participants was distorted. In
Ostergaard 2000, students randomised to the intervention arm
weremore likely to agree to take part (48%, 1254/2603) than those
randomised to the control arm (38%, 1097/2884). In Scholes
1996, women randomised to the intervention group were actively
encouraged to complete the risk assessment questionnaire. The
planned ratio of intervention to control was 1:2, while the actual
ratio of enrolled women was 1:1.6 (1009 intervention, 1598 con-
trol).
The risk of bias in allocation concealment was unclear in van den
Broek 2012. The intervention was allocated and implemented in
two stages. Allocation was not random, but the investigators who
assigned 191 postal areas to intervention and control groups were
blinded to their identity. The invitationswere sent out in a random
order.
Blinding
The two trials reporting the primary outcome of chlamydia preva-
lence did not explicitly mention that laboratory staff were blinded,
but we considered the risk of detection bias to be low because the
C. trachomatis test result reporting was automated (Garcia 2012;
van den Broek 2012).
The risk of performance biaswas high inRCTs that sent invitations
or instructions for sample collection only to participants in the
intervention group (Andersen 2011; Ostergaard 2000; Scholes
1996). Advice about healthcare-seeking behaviour for symptoms
related to upper genital tract infection might result in differences
in management compared with participants in the control groups.
Detection bias was possible for the primary outcome PID, which
20Screening for genital chlamydia infection (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
is a subjective diagnosis based on clinical findings. Assigning a
diagnosis of PID can be influenced if the assessor knows whether
a person has received screening and treatment for chlamydia or
not. We considered Oakeshott 2010 to be at low risk of detection
bias because a panel of independent experts used pre-specified
criteria to assign the outcome PID. We also deemed Andersen
2011 to be at low risk of detection bias because outcomes were
extracted from hospital discharge and prescription registers. In the
trial by Scholes 1996 the risk of detection bias was unclear; people
abstracting information from medical records were unaware of
group allocation, but investigators did not explicitly describe the
blinding of those assigning outcome diagnoses. In Ostergaard
2000 the risk of detection bias was high because outcome assessors
were not reported to have been blinded. In the trial by van den
Broek 2012 the risk of detectionbiaswas high because investigators
only collected data from women who responded to the screening
invitation, and the response rate within this group to questions
about self reported PID was very low.
Incomplete outcome data
In trials reporting the primary outcome of chlamydia prevalence,
attrition was high in van den Broek 2012. Garcia 2012 did not
measure attrition from participation in the intervention, but par-
ticipation in surveys to assess the outcome was high.
In trials that reported the primary outcome of PID, the risk of
attrition bias was low in Andersen 2011, Oakeshott 2010 and
Scholes 1996 and high in Ostergaard 2000 and van den Broek
2012.
Selective reporting
There was a risk of reporting bias in three RCTs that did not have
a protocol (Andersen 2011; Ostergaard 2000; Scholes 1996). The
reported results matched the methods, so we assessed the risk of
bias as unclear. We judged the remaining three trials to be at low
risk of reporting bias.
Other potential sources of bias
There was a risk of contamination of the intervention in three
trials (Andersen 2011; Oakeshott 2010; van den Broek 2012).
We considered the risk to be high in Oakeshott 2010 and unclear
in the other two trials. Three trials reported receiving funding
from diagnostic or pharmaceutical companies (Oakeshott 2010;
Ostergaard 2000; Scholes 1996).We assessed the risk that this had
resulted in biased results to be unclear in all three trials.
Effects of interventions
See: Summary of findings for the main comparison
Primary outcomes
C. trachomatis transmission
The three included trials that evaluatedC. trachomatis transmission
used different populations, screening interventions, study designs
and follow-up periods (Garcia 2012; Ostergaard 2000; van den
Broek 2012). The effect measure differed in each trial. We could
not generate a common effect measure because all were cluster
trials and none reported an ICC. We describe the results of each
trial separately and report results in Table 1.
In the general adult population, van den Broek 2012 found no
statistical evidence of a difference in overall chlamydia test posi-
tivity in intervention compared with control clusters after the first
(baseline, 4.3% vs 4.3%), second (12 months, 4.0% vs 4.3%) and
third (24 months, 4.1% vs 4.3%) invitations (numbers invited
differed between screening rounds, see Table 2 for details). Anal-
ysis 1.1 shows the results as the risk ratio (RR) comparing second
and third rounds with the first round. The results for women and
men separately were similar. The results from analyses at the indi-
vidual level, with clustering taken into account, were the same.We
graded the quality of the evidence to be low, as data from non-ran-
domised trials begin at low quality. We would have downgraded
this evidence further because there were no other trials and be-
cause of uncertainty about the effect of this intervention at higher
sustained levels of uptake. However, the trial was very large, at low
risk of other biases and it is unclear whether, in practice, the lack
of randomisation resulted in biased allocation.
Garcia 2012 found a lower risk of chlamydia infection in female
sex workers in intervention compared with control cities in 2006
(RR 0.72, 95% CI 0.54 to 0.98, 4465 women). Amongst female
sex workers tested in 2002 (baseline), prevalence was 13.8% in in-
tervention vs 15.5% in control cities, and in 2006 (at 48 months),
it was 9.9% in intervention vs 14.5% in control cities.We adjusted
the analysis for differences in prevalence between intervention and
control groups in 2002, but not for the pairing of intervention
and control cities. We downgraded the quality of the evidence for
this outcome to low because directeness and only one trial assessed
screening in this population.
Reproductive tract morbidity in women
In five trials that reported the incidence of clinically diagnosed
PID, follow-up data at 12 months were available for 100% of par-
ticipants either invited to be screened or in the control group in the
RCT by Andersen 2011, 94% in Oakeshott 2010, 76% in Scholes
1996, and 55% in Ostergaard 2000. In the cluster-controlled trial
by van den Broek 2012, information was not available from all
women invited; from those who responded to the screening invi-
tation, information was available for 3.6% in the control group
and 11.2% in the intervention group after the first 12-month in-
tervention period. We applied a design effect of 1.608 (average
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cluster size 100) to data extracted from the trial by Ostergaard
2000.
Intention-to-treat analysis (Analysis 1.2, Figure 4): We calculated
the risk ratio of clinically diagnosed PID in women invited to be
screened compared with women who were not invited or who had
deferred screening (Andersen 2011; Oakeshott 2010; Ostergaard
2000; Scholes 1996). This analysis assumed that women whowere
not followed up at 12 months did not develop PID. The risk of
PIDwas lower inwomen in intervention than control groups, with
little evidence of between-trial heterogeneity (RR 0.68, 95% CI
0.49 to 0.94, I2 7%, 4 trials, 21,686 participants). We found one
trial that provided results in women who had a positive chlamydia
test result at baseline (Oakeshott 2010). PID incidence was much
lower in women who received immediate treatment (1/64) than
those who received deferred treatment (7/74, RR 0.17, 95% CI
0.03 to 1.01). In women in the same RCTs with complete data
at follow-up, the risk of PID in the intervention group was 32%
lower than in the control group (RR 0.68, 95% CI 0.49 to 0.93,
I2 0%).
Figure 4. Forest plot of comparison: 1 Offer of chlamydia screening vs usual care (inactive control),
outcome: 1.2 Incidence of PID at 12 months (intention-to-treat).
Data from the non-randomised cluster-controlled trial by van
den Broek 2012 were not combined with RCT data. The authors
reported results according to screening round; in women who
provided information, the incidence in the previous 12 months
was 1.8% (19/1072) at the first invitation, 2.1% (47/2261) at
the second invitation and 1.9% (44/2340) at the third invitation.
Using data from the first two screening rounds, we calculated a
design effect of 1.119 (average cluster size 20.3).
For our sensitivity analyses, we analysed the results separately for,
on the one hand, Andersen 2011 and Oakeshott 2010, two RCTs
at low risk of selection bias and bias for detecting PID, and, on
the other, Ostergaard 2000 and Scholes 1996, two trials at high
or unclear risk of bias. Within these groups there was no evidence
of between trial heterogeneity (I2 0%). The estimated effect of
chlamydia screeningwas less strong inRCTs at low risk of detection
bias than in RCTs at high or unclear risk of detection bias (Analysis
1.2, P = 0.10; Analysis 1.3,). In the intention-to-treat analysis, the
risk of PID in women invited for screening was 20% lower than
for those whose were not in RCTs at low risk of detection bias
(RR 0.80, 95% CI 0.55 to 1.17, 2 trials, 18,022 participants) and
53% lower in RCTs at high or unclear risk of detection bias (RR
0.47, 95% CI 0.26 to 0.84) (2 trials, 3664 participants).
We downgraded the quality of the evidence to moderate because
of statistical evidence that detection bias might have overestimated
the intervention effect.
Reproductive tract morbidity in men
The trial by Andersen 2011 was the only one to provide informa-
tion about epididymitis in men. Men invited for screening had a
20% lower risk for epididymitis than those not invited (RR 0.80,
95% CI 0.45 to 1.42, 1 trial, 14,980 participants). The effect size
is similar to that observed for PID for women in the same trial, but
the number of events in menwas smaller so the confidence interval
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is wider and includes the possibility of no effect. We downgraded
the quality of the evidence to very low because risk of bias and
there was only one trial with low uptake of the screening interven-
tion.
Chlamydia infection in pregnancy
We did not find any trials of chlamydia screening in pregnant
women.
Secondary outcomes in all participants
Uptake of chlamydia screening
The included trials did not calculate uptake of the chlamydia
screening intervention uniformly, owing to differences in trial de-
sign. Table 2 shows the data reported in each trial.
Harms of screening
None of the included trials reported any harms of screening.
Secondary outcomes in non-pregnant women
Female infertility
The trial by Andersen 2011 was the only one to provide informa-
tion about infertility in women, assessed up to nine years after a
single round of the screening intervention. The risk of infertility
was 15% higher in women invited to be screened compared with
those not invited; the number of events was small so the confi-
dence interval is wide and compatible with no effect (RR 1.15,
95% CI 0.94 to 1.40, 1 trial, 15,459 participants, very low quality
evidence).
Ectopic pregnancy
The trial by Andersen 2011 was the only one to provide infor-
mation about ectopic pregnancy, assessed up to nine years after a
single round of the screening intervention. There was no evidence
of a difference in the risk of ectopic pregnancy in women invited
to be screened compared with those not invited (RR 1.03, 95%
CI 0.67 to 1.60, 1 trial, 15,459 participants, very low quality ev-
idence).
Subgroup and sensitivity analyses
There were too few included trials for subgroup analyses or sensi-
tivity analyses other than the one reported above for reproductive
tract morbidity in women.
D I S C U S S I O N
Summary of main results
We found six trials that investigated the effect of chlamydia screen-
ing interventions on either C. trachomatis transmission (one RCT,
one cluster-controlled trial) or reproductive tract morbidity (three
RCTs, one cluster-RCT). We found no trials assessing the effects
of chlamydia screening in pregnancy on obstetric or neonatal out-
comes. One trial in the Netherlands found no effect of register-
based yearly invitations in the general population, but uptake of
the intervention was low. One trial in Peru found that mobile
teams offering periodic testing and treatment for sexually trans-
mitted infections in female sex workers reduced the prevalence of
chlamydia infection. Four RCTs found a reduction in the inci-
dence of clinically diagnosed PID in women (RR 0.67, 95% CI
0.49 to 0.92) 12 months after a single offer of chlamydia screen-
ing. The quality of this evidence was downgraded from high to
moderate because of statistical evidence that the effect of the in-
tervention was less strong in trials with a low risk of detection
bias compared with trials at high or unclear risk. One trial found
no statistical evidence of an effect of chlamydia screening on epi-
didymitis, female infertility or ectopic pregnancy.
Overall completeness and applicability of
evidence
We aimed to assess evidence about the effects of chlamydia screen-
ing interventions on transmission of C. trachomatis infection, re-
productive tract morbidity and pregnancy and neonatal outcomes.
We found a small number of trials assessing outcomes in non-preg-
nant women andmen and no trials of chlamydia screening in preg-
nancy (Andersen 2011; Garcia 2012; Oakeshott 2010; Ostergaard
2000; Scholes 1996; van den Broek 2012).
Trials of the effect of screening on C. trachomatis transmission
aimed to measure effects on chlamydia prevalence but not on
chlamydia incidence. van den Broek 2012 focused on the general
population, Ostergaard 2000 on school students and Garcia 2012
on female sex workers, all attempting to measure prevalence as an
outcome. Garcia 2012 and van den Broek 2012 implemented the
intervention overmore than one screening round, which acknowl-
edges screening as an ongoing process. Multiple screening rounds
need to be done for infections like chlamydia because people who
have been treated become susceptible to further infections from
untreated partners or from new infected partners.
van den Broek 2012 found that the uptake of register-based postal
invitations for screening in theNetherlands was very low and there
was no reduction in the proportion of positive tests after three
rounds of screening. This trial was done in a pragmatic way and
these results are applicable to all settings. In contrast, Ostergaard
2000 found that a subset of female school students with very high
screening uptake at baseline had a lower prevalence of chlamydia
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after 12 months than women who had not been screened. The
generalisability of this finding is unknown because attrition was
high, and there was no long-term follow-up of the sustainability of
the intervention. Between these extremes, the precise relationship
between screening uptake and change in chlamydia prevalence re-
mains unknown. Mathematical modelling studies show that up-
take is the strongest determinant of the impact of screening on
chlamydia prevalence over time (Althaus 2010; Regan 2008).
Trials of the effects of chlamydia screening interventions on PID
mostly assessed the effects of a single round of screening (Andersen
2011; Oakeshott 2010; Ostergaard 2000; Scholes 1996). It is not
known whether the effect size stays the same over time. van den
Broek 2012 found no change in self reported PID over three
rounds of invitations for chlamydia screening. Uptake of screening
was low and information about PID was only available for a small
minority of eligible participants, so this trial could not address the
question.
Evidence about the effects of chlamydia screening on epididymitis
and on female infertility and ectopic pregnancy is incomplete.
Only one trial examined these outcomes following a single offer
of a screening test and found no strong statistical evidence of an
effect on any of them (Andersen 2011). Uptake and intensity of
the intervention in this trial might have been too low to have a
measurable impact on rare and long-term outcomes.
RCT evidence about the effects of chlamydia screening in preg-
nancy is lacking.
Quality of the evidence
The quality of evidence about the effects of chlamydia screening
interventions is influenced by the small number of trials and the
risk of bias. For any trial, we could only assess whether there was a
risk of biased results, and not whether the results themselves were
or were not biased.
The paucity of trials assessing chlamydia prevalence or incidence
as an outcomemeans that we are very uncertain about the effects of
chlamydia screening for preventing transmission of C. trachomatis
in high risk individuals and the general population (Garcia 2012;
van den Broek 2012). In the general population, the large trial by
van den Broek 2012 provides a precise estimate for that particu-
lar intervention. Additional trials that evaluate different interven-
tions with higher and sustained coverage might well find different
results. The trial by Garcia 2012 in high risk populations was at
low risk of bias, but the findings might not be applicable to other
settings and interventions.
For the effect of chlamydia screening on reducing the risk of PID,
the summary risk ratio might overestimate the effect because of
the risks of selection and detection bias in some trials. Whilst the
findings of the four RCTs were statistically compatible (I2 7%),
the effect sizes in individual trials varied frommodest in Andersen
2011 andOakeshott 2010 to large inOstergaard 2000 and Scholes
1996. We pre-specified sensitivity analyses according to the risks
of selection and detection bias. Two trials were at high or unclear
risk of both of these biases, and these trials showed the largest
effects (Ostergaard 2000; Scholes 1996).
Potential biases in the review process
The search strategy was broad and unlikely to have missed RCTs.
We followed the protocol reasonably closely and did not undertake
any non-specified subgroup analyses.
Agreements and disagreements with other
studies or reviews
This review updates systematic reviews of literature published up
toOctober 2007 and August 2012 (ECDC 2014; Low 2009). The
current review identifiednew studies about the effects of chlamydia
screening on both C. trachomatis transmission and reproductive
tract morbidity (PID, infertility and ectopic pregnancy in women,
epididymitis in men). Narrative reviews have also addressed this
research question (Gottlieb 2010; Gottlieb 2013). The main con-
clusions of these reviews agree with each other.
The modelling study by Herzog 2013 examined the direct effect
of identifying and treating asymptomatic infections on the risk
of clinically diagnosed PID. It is assumed in this study that a fall
in the incidence of PID is the direct result of antimicrobial treat-
ment of a prevalent chlamydia infection. A fall in PID incidence
in clinical trials of women who might have been infected with
chlamydia many months before enrolment suggests that symp-
toms can develop throughout the course of a lower genital tract
chlamydia infection. This finding contradicts the assumption that
PID resulting from ascending chlamydial infection occurs at the
beginning of the infectious duration.
Chlamydia screening can also have an indirect effect on the risk
of PID (Herzog 2013). If screening and treatment are sustained at
high enough levels, the prevalence of chlamydia infection should
fall, and exposure to the risk of chlamydia should also decrease.
Gottlieb 2013 and colleagues suggest that PID incidence at the
population level can fall, even if chlamydia prevalence stays the
same. A screening intervention could detect and treat chlamydia
infections and shorten the average duration of infection. Women
who have received treatment are susceptible to infection again.
The rate of incidence of C. trachomatis infections following treat-
ment might then increase so the net effect would be to main-
tain prevalence. It is not clear what levels of chlamydia screening
would result in this apparently paradoxical effect. In the trial by
van den Broek 2012, at the low levels of chlamydia screening up-
take achieved, neither chlamydia positivity in the tested popula-
tion nor self reported PID decreased.
The outcome measured in the included trials was PID from all
causes. Only the trial by Oakeshott 2010 collected information
about PID in women with and without C. trachomatis at baseline.
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In this subset of women, investigators assumed that PID diag-
nosed during the trial was caused by untreated chlamydia infec-
tion. The risk of chlamydia-associated PID in screened compared
with unscreened women was 83% lower (RR 0.17, 95% CI0.03
to 1.01). C. trachomatis is only one cause of PID, however. The
reduction in PID at the population level if chlamydia screening
overall population might therefore be modest if the population
attributable fraction is small.
Ongoing studies should provide more evidence about the effects
of opportunistic chlamydia screening interventions on chlamydia
prevalence in young adults in the general population (Hocking
2010; Lehtinen 2015).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Detection and treatment of chlamydia infection can reduce the
risk of PID in an individual woman. The size of the effect is
uncertain because of methodological biases in some trials that
could exaggerate the effect of the intervention. It is not known
whether chlamydia screening to prevent PID has an impact on
rates of infertility and ectopic pregnancy.
The effect of register-based chlamydia screening for C. trachoma-
tis transmission in young adults in the general population is un-
certain. The results of ongoing trials of opportunistic chlamydia
screening are pending.
There is an absence ofRCTevidence about the effects of chlamydia
screening in pregnancy and of the harms of chlamydia screening.
Implications for research
RCTs of chlamydia screening in pregnancy and men are neces-
sary for determining both benefits and harms. RCTs of chlamydia
screening interventions in high risk populations such as sex work-
ers are necessary to replicate the findings of Garcia 2012.
Diagnostic tests to improve the accuracy of diagnosing PID would
help to improve outcome ascertainment inRCTs.RCTsof chlamy-
dia screening interventions to prevent PID should determine the
effects of repeated rounds of screening on the incidence of chlamy-
dia-associated PID and chlamydia reinfection.
RCT evidence about the effects of chlamydia screening on infer-
tility and ectopic pregnancy would be valuable. There are substan-
tial methodological challenges involved in using these conditions
as trial outcomes. Non-invasive diagnostic tests for fallopian tube
damage or blockage might provide surrogate markers for tubal
factor infertility.
Mathematical modelling and evidence synthesis studies should
be conducted to determine whether chlamydia screening inter-
ventions that reduce PID incidence are compatible with stable
chlamydia prevalence at the population level.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Andersen 2011
Methods Study design:
Setting: population-based screening programme in Aarhus county, Denmark
Study duration: 1 year from screening test offer for PID and epididymitis; 9 years from
screening offer for ectopic pregnancy and infertility
Participants Young adult population (aged 21-24 years) 30,439 eligible individuals (15,459 women,
14,890 men)
Inclusion criteria
• Women and men born in 1974, 1975, or 1976
• Living in the county of Aarhus on 13 October 1997 (aged 21-24 years at
initiation of the study).
Exclusion criteria:
• non-Danish citizens (missing personal identification number (CPR number))
Interventions Enrolment: through population registry
Intervention group:invitation for CT testing, N = 9000 (4000 women, 5000 men)
All participants in the intervention group received an invitation by direct mail to be
tested for C. trachomatis by taking a sample at home and mailing it directly to the
diagnostic laboratory. The intervention group was further subdivided into 2 randomly
assigned groups (group 1 and group 2), each containing 2000women and 2500men. The
difference between intervention groups 1 and 2 was that group 1 participants received
the test package together with the invitation, whereas group 2 participants had to return
a franked, preaddressed reply card to the study centre to receive the test package. (For the
purpose of current analysis, we merged the data for the 2 types of approach strategies.)
Co-interventions: Infected individuals received instructions to contact a general prac-
titioner (GP) for medical treatment and partner notification. People in the intervention
groups also had the opportunity of receiving usual care, which consisted of swab samples
obtained at a physician’s office. All C. trachomatis positive individuals also received a
second offer to be tested for the infection by the use of a mail-in home-obtained sample
24 weeks after the initial test
Control group: usual care, N = 21,439 (11,459 women, 9980 men)
No contact during the study period. Individuals in the intervention groups as well as
those in the control group had the opportunity of usual care consisting of an endocervical
and/or urethral swab sample taken by a physician in office. Free testing is available in
Denmark. At 3 months 9.4% of women in the control group and 9.0% of women in
the intervention group had been tested as part of usual care. For men, the corresponding
figures were 1.4% and 1.5% for the 2 groups, respectively
Co-interventions: There are no recommendations with regard to repeated testing in any
age group, but, as a general rule, samples are taken because of symptoms or intrauterine
procedures such as induced abortion or insertion of an intrauterine device (Andersen
2002)
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Andersen 2011 (Continued)
Outcomes Primary outcomes
• Incidence of upper genital tract infection in women in the 12 months after the
offer of screening (intervention group vs control group)
• Incidence of upper genital tract infection in women in the 12 months after the
offer of screening (intervention group only; non-participants vs participants)
• Incidence of epididymitis in men in the 12 months after the offer of screening
(intervention group vs control group)
• Incidence of epididymitis in men in the 12 months after the offer of screening
(intervention group only; non-participants vs participants)
Secondary outcomes
• Proportion of participants receiving the intervention at 3 months (uptake of
screening)
Investigators followed the entire study population (comprising individuals who accepted
the test offer, those who did not and the control group) using central governmental
registers during the first year after the test offer to assess the rates of PID (women)
or epididymitis (men) diagnosed according to the Danish versions of the International
Classification of Disease Codes (ICD-10)
Notes The study was approved by the local ethical committee in the county of Aarhus
and by the Danish Data Protection Agency. Trial registration: www.clinicaltrials.gov
NCT00827970. This study received financial support from the Danish Medical Re-
search Council (grant no 22-02-0540), the NOVO Foundation and the Research Foun-
dation in Aarhus County
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Comment: computer-based randomisation
Allocation concealment (selection bias) Low risk Comment: Individuals selected for screen-
ing invitation did not know there was a
control group, so unlikely to have affected
decision to take part or not; control group
did not know they were in a trial
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Comment: Blinding was not used. Partic-
ipants in intervention group might receive
different advice about risks of upper genital
tract infection and about what to do if they
have symptoms. Control group did not re-
ceive any information
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comments: Data on blinding of outcome
assessment was not provided. The review
authors judge that the outcome is not likely
to be influenced by lack of blinding
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Andersen 2011 (Continued)
The same applies for both primary out-
comes: PID and epididymitis
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: The same applies for both pri-
mary outcomes: PID and epididymitis
Selective reporting (reporting bias) Low risk Comment: The study protocol is not avail-
able, but it is clear that the published re-
ports include all expected outcomes, in-
cluding those that were pre-specified (con-
vincing text of this nature may be uncom-
mon)
Other bias Unclear risk Contamination is a risk, if women in the
control group continued to be tested at the
same rate as during the study period, the
percentage tested by the time the outcome
PIDwas measuredmight have been higher.
This could reduce the size of any difference
between intervention and control groups.
Not enough information to know what
proportion of control groupwas tested dur-
ing the follow-up period
Garcia 2012
Methods Study design: cluster-randomised trial of a multicomponent intervention for the pre-
vention of sexually transmitted disease in female sex workers and the general population
Setting: urban communities in Peru
Study duration: 4 years
Participants Female sex workers (FSW). 24 cities assessed for eligibility. 20 cities cluster-randomised
in 10 pairs, 4483 FSW (range 75-209 per city enrolled, 4465 provided samples, 4413
completed survey)
Inclusion criteria:
• Cities with > 50,000 inhabitants
Exclusion criteria:
• Lima (too big), cities taking part in other STI intervention trials
Interventions Enrolment: All eligible cities randomised. Sex venues “includ[ing] brothels, bars, night-
clubs, street-based venues and truck stops” were mapped and visited by mobile teams
(in all 24 cities assessed for eligibility). Baseline survey participants were non-randomly
sampled, consecutive FSW from all venues in a city or until 200 FSW per city sampled
(p. 1121). In intervention cities only, mobile teams approached FSWs in sex venues in
spaces varying from private bedrooms to small side rooms at bars. The baseline survey
took place from November 2002 to April 2003, outcome surveys and sampling took
place from September to December in both 2005 and 2006
Intervention group (median population 190,102, range 54,148-272,231)
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Garcia 2012 (Continued)
Quote: “We created mobile teams and laboratory support systems in intervention cities
to deliver clinical and preventive services to FSWs from July, 2003, to December, 2006.
Eachmobile teamwas made up of a nurse or midwife and an FSW peer educator. Mobile
teams’ activities included two visits to each sex venue in each of 20 cycles of 8 weeks
to provide periodic presumptive treatment with metronidazole for trichomoniasis and
bacterial vaginosis to FSWs who were not pregnant or breastfeeding, and willing to
forego alcohol consumption for 72 h. Self obtained vaginal swabs were collected for local
T vaginalis culture and for nucleic acid amplification in Lima for N gonorrhoea and C
trachomatis. The teams returned 1 week later, providing test results and treatment for
specific infections identified (ciprofloxacin for gonorrhoea, azithromycin for chlamydia,
andmetronidazole for positive T vaginalis cultures not treated a week earlier). FSWswere
encouraged to visit local government clinics for periodic syphilis and HIV testing, and
for interim STI symptoms. Laboratory technicians joined mobile teams from February,
2005, to December, 2006, and did rapid syphilis testing.”
Co-interventions: “Mobile teams also provided motivational interviewing to promote
condomuse by sexworkers, and gave up to 15 condoms to each FSW in each 8week cycle
in the first 1.5 years, then increased to 50 condoms per cycle. For the general population,
the local non-governmental organisation APROPO implemented social marketing of a
low-cost condom, theOK condom, through pharmacies in intervention cities only, from
October, 2003, to October, 2004, then more widely.”
Control group: usual care:10 cities (median population 135,187, range 50,183-291,
408)
Usual care: “status quo services”, no other description reported
Outcomes Primary outcomes
• Prevalence of chlamydia infection (chlamydia test positivity) measured at baseline,
3 years and 4 years
• Composite STI prevalence ( Chlamydia, gonorrhoea, trichomonas, syphilis, HIV)
measured in at baseline, 3 years and 4 years
Secondary outcomes
• none
Each sex venue visited during 20 cycles lasting 8 weeks each. Continuous mapping to
record closed down and new venues.For evaluation surveys, FSW surveyed by quota
sampling individuals at randomly selected venues and times
Notes Institutional review boards at the University of Washington, Universidad Peruana
Cayetano Heredia, and US Naval Medical Research Center Detachment approved the
protocol, consent forms, and instruments. Eligible FSWs older than 14 years and sur-
vey participants provided verbal consent. Trial registration: ISRCTN43722548. This
research was supported by the Wellcome Trust-Burroughs Wellcome Fund Infectious
Disease Initiative 059131/Z/99/Z, 078835/Z/05/Z, and 078835/Z/05/B; National In-
stitutes of Health NIAID STDCooperative Research Center AI31448, Center for AIDS
Research AI27757, and CIPRA U19 AI053218; and USAID-Peru
Risk of bias
Bias Authors’ judgement Support for judgement
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Garcia 2012 (Continued)
Random sequence generation (selection
bias)
Low risk Comment: computer-generated randomi-
sation sequence (see below)
Allocation concealment (selection bias) Low risk Quote: “Within each pair, one city was ran-
domly assigned to an intervention with an
S-PLUS (version 3·1) program written by
JPH; the other citywas assigned to standard
care.” (p. 1121), Comment: No chance to
know allocation in advance or to change
once allocated
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “US and UK investigators (except
JPH) were masked to identities of inter-
vention cities until completion of all sur-
veys and laboratory testing.” “Fieldworkers
and the Peruvian study team could not be
masked.” (p. 1121)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “Laboratory personnel and the data
analyst (KKT) weremasked to assignments
until final analysis.” (p. 1121)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: very high participation in cross-
sectional surveys
Selective reporting (reporting bias) Low risk Comment: primary outcome same as in
protocol and in the trial registration
Other bias Low risk -
Oakeshott 2010
Methods Study design: Individually randomised controlled trial comparing immediate with de-
ferred screening
Setting: common rooms, lecture theatres, and student bars at universities and further
education colleges in London.
Study period: 1 year from acceptance of offer of chlamdia testing
Participants Sexually active female students 16-27 years (N = 2563)
Inclusion criteria:
• Aged 27 or less
• Sexually active females
Exclusion criteria:
• Never had sexual intercourse
• Had been tested for chlamydial infection in the past 3 months
• Pregnant
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Oakeshott 2010 (Continued)
Interventions Enrolment: Investigators personally recruited women in bars, common rooms and lec-
ture theatres at 20 London universities and further education colleges, randomising them
between September 2004 and October 2006
Intervention group: screening:1273 women randomised (but 14 excluded = 1259
included)
Vaginal swab samples were obtained (at nearest lavatory) and analysed for C. trachomatis.
In case of infection the woman was contacted and urged to contact a physician for
treatment and partner notification
Control group:deferred screening:1290 randomised (but 20 excluded = 1270 in-
cluded)
Samples were obtained (at nearest lavatory) but stored for 12 months. Women were
obliged to seek a health care provider if they considered themselves at risk or if they had
symptoms (= standard care)
Outcomes Primary outcomes
• Incidence of pelvic inflammatory disease in women evaluated in the 12 months
after recruitment; assessed by a doctor as probable, with a clinical diagnosis of PID
which was treated (modified Hager’s criteria - pelvic pain, cervical motion tenderness,
uterine or adnexal tenderness)
• Incidence of pelvic inflammatory disease in women evaluated in the 12 months
after recruitment; assessed by a doctor as possible, with clinical features of PID
(abdominal pelvic pain with features of PID, which may have responded to
antimicrobial therapy, but no record of cervical excitation or uterine or adnexal
tenderness; or longstanding abdominal pain consistent with endometriosis, but some
features of PID - for example, uterine tenderness, and unable to confirm if
antimicrobial therapy had a benefit)
Secondary outcomes: none reported
Outcomes measured via questionnaires, answered by participants by e-mail, postal ques-
tionnaires or telephone calls. Non-responders were followed up by contacting a GP
Notes The study was approved by Wandsworth research ethics committee (reference 03.0012)
. Trial registration number: NCT00115388. This study was supported by the BUPA
Foundation (grant No 684/GB14B). TMA sample collecting kits were provided byGen-
Probe (San Diego, CA)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Comment: random number tables were
used (p. 2).
Allocation concealment (selection bias) Low risk Comment: Sealed sample packs, which
contained the completed, unopened ques-
tionnaires and consent formswere allocated
(blinded procedure) (p. 2)
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Oakeshott 2010 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Comment: Participants were blind to
group allocation except for those in the
interventions group with baseline samples
that tested positive for chlamydia and who
were referred for treatment and 38 women
with indeterminate test results who were
asked to post a repeat sample (masking p.
2). Samples were obtained before alloca-
tion and therefore the recruiting personnel
could not be aware of allocation. Not clear
what happened with indeterminate results
in control group if tested after 12 months
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: A panel of 3 genitourinary
medicine physicians assessed patient ques-
tionnaires and medical records using stan-
dardised criteria; they were blinded to trial
group (p. 2)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: In the intervention group, 68
were lost to follow-up; in the control group
84 were lost to follow-up. These numbers
are very low and unlikely to influence the
results
Selective reporting (reporting bias) Low risk Comment: The single primary aim from
the protocol is reported in the publication
2 primary aims from the introduction sec-
tion are reported in the results. The proto-
col is available
Other bias High risk Contamination of intervention: possibility
of independent testing in the year of the
study, which would reduce differences be-
tween the intervention and control group
(about 22% in each group were tested);
Received funding of diagnostic tests from
manufacturer.
Ostergaard 2000
Methods Study design: cluster-randomised controlled trial
Setting: 17 high schools in Aarhus county, Denmark
Study duration: 1 year after the offer of screening
Participants High school female students in Aarhus region aged 15-19+ years (N = 5487 randomised,
N = 1700 provided follow-up data)
Inclusion criteria:
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Ostergaard 2000 (Continued)
• All 17 high schools in Aarhus county
• Female students who were sexually experienced
Exclusion criteria: not mentioned
Interventions Enrolment: The report does not include a description about how schools were ap-
proached or how home sampling kits/instructions for control arm were given. Possibly,
investigators may have used the baseline questionnaire to identify sexually experienced
students (“eligible responders”), telling these to return specimen. Enrolment took place
between January and April 1997
Intervention group: home sampling:2603 women in 8 schools
Quote: “[H]ome sampling kits given to the students at the end of gatherings at which
information about the C. trachomatis diseases and the study was given. The home sam-
pling kit consisted of a vaginal pipette (containing 5 mL sterile sodium chloride) for
obtaining vaginal flush samples (women) and a urine sample (men), a questionnaire,
written instructions on how to obtain the sample, and a self-addressed, stamped enve-
lope. Students were instructed to administer the vaginal pipette for sampling on receipt.
The samples obtained at home weremailed by the students directly to theDepartment of
Clinical Microbiology, where they were analyzed. The students also provided the address
where the test results were to be sent. Students with positive test results were requested
in writing to visit a doctor for treatment and partner tracing and to take a letter to the
doctor.” (p. 952)
Control group:usual care:2884 women in 9 schools
Quote: “The control group received the same information and questionnaire as the home
sampling group, but they were not supplied with the home sampling kit. Instead, they
were offered a free testing at the local clinic for sexually transmitted diseases (STDs) or
at the office of any other physician, including that of their general practitioner.”
Outcomes Primary outcomes
• Prevalence of chlamydia infections after 1 year of follow-up
• Incidence of pelvic inflammatory disease in women (self reported) measured in
the 12 months after the offer of testing
Secondary outcomes
• Incidence of pelvic inflammatory disease requiring hospitalisation in women
measured in the 12 months after the offer of testing
A questionnaire was sent to participants asking for “information about treatment for
PID and admittance to a hospital for PID during the year of follow-up. In an attempt to
verify that treatment for PID had been given, every student who reported treatment for
PID was sought among all records of antimicrobial prescriptions at the central Danish
register for prescriptions (Lægemiddelstyrelsen).”
Notes The study was funded by the Danish National Board of Health (grant No 210 i 1997)
, Løvens Kemiske Fabriks Research Foundation, Nycomed DAK, Pfizer, and Chairman
Jacob Madsen and Hustru Olga Madsen’s foundation
Risk of bias
Bias Authors’ judgement Support for judgement
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Ostergaard 2000 (Continued)
Random sequence generation (selection
bias)
Low risk Quote: “All 17 high schools in the county
of Aarhus, Denmark, were cluster-ran-
domised 1:1 by simple redeeming (draw-
ing lots from a hat) into an intervention
(home sampling) group consisting of 8high
schools composed 2603 women and 1733
men, and a control group consisting of 9
high schools composed 2884 women and
1689 men.”
Allocation concealment (selection bias) High risk Comment: not described, but randomi-
sation was done before asking for con-
sent.More students in the intervention arm
(48%, 1254/2603) than the control arm
(38%, 1097/2884) agreed to take part. At
a subsequent stage, women were asked to
consent to be followed up for the out-
come PID. A lower proportion of the sex-
ually experienced women in the interven-
tion arm (93%, 867/928) than the control
arm (100%, 833/833) agreed to follow up
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Comment: no blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Comment: Participants self assessed PID.
Possibility of detection bias. Investigators
checked prescription records, and there was
no statement about blinding
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: Almost 50% inboth groups lost
to follow-up (intervention, 51%, 43/867;
control 58%, 487/833)
Selective reporting (reporting bias) Unclear risk Comment: testing in follow-up period not
reported, which might influence primary
outcome and determine PID outcome. No
protocol was available, so the risk of report-
ing bias is unclear
Other bias Unclear risk Received funding from pharmaceutical
company
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Scholes 1996
Methods Study design: Randomisation before assessment of eligibility or obtaining consent for
participation
Setting: staff-model health maintenance organization (HMO) located in westernWash-
ington State, USA
Study duration: 1 year afer offer of screening to intervention group
Participants Enrolment: Women aged 18-34 years enrolled in a health maintenance organization
(HMO) on 1 October 1990 (N = 36,547 received an initial questionnaire on eligibility;
N = 2607 randomised). Duplicate surveys were mailed to non-responders. Telephone
calls were made to some of the non-responders, focusing on those in the intervention
group
Inclusion criteria:
• Women in the target age group with no spouse registered who had a certain risk
score based on criteria related to: age, race, gravidity, vaginal douching in the preceding
12 months, and number of sexual partners in the preceding 12 months
Exclusion criteria:
• Pregnant, sexually inexperienced, hysterectomised or married women
• Women with regular use of antibiotics
Interventions Intervention group: screening:1009 women enrolled
Invitation to be tested for C. trachomatis by use of 2 cervical samples that were analysed
by ELISA and culture, respectively. All women with a positive test result were treated for
chlamydia infection by their primary care provider
Control group: usual care:1598 women enrolled
No intervention; women in the usual care group saw their health care providers as needed
Outcomes Primary outcomes
• Incidence of pelvic inflammatory disease in women. The diagnoses were retrieved
after 12 months but records for the preceding 12 months were evaluated. Several
sources were used to identify women who could have had a PID: questionnaire
answered by included women, assignment to or discharge from the hospital with a
diagnostic code indicating PID or cervicitis, positive test for C. trachomatis or with 10-
day courses of doxycycline. Medical records from these women were reviewed to
identify PID cases.
Secondary outcomes:none reported
Notes All study procedures were reviewed and approved by the institutional review unit at the
HMO. It is not clear to what extent this includes ethical approval. Supported in part by
a grant (A1-24756) from the National Institute of Allergy and Infectious Diseases and
by a grant from Bristol-Myers Squibb
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: method not stated. Quote:
“The womenwere randomly assigned to ei-
ther the screening group or the usual-care
group at the time the original sample was
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Scholes 1996 (Continued)
selected in October 1990.”
Allocation concealment (selection bias) High risk Comment: Investigators made special ef-
forts in the intervention group to increase
participation rate. As a result, the inten-
tion was a 1:2 randomisation but the study
ended up with 1:1.5
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Comment: no blinding. The lack of par-
ticipant blinding and the outcome evalua-
tionpartly based onquestionnaire datamay
have influenced the results, making women
in intervention group more aware of PID
symptoms and therefore causing an under-
or overestimationof the intervention effect.
No information about if the 76% complet-
ing the questionnaire were from interven-
tion or control group
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote: “The abstracters were unaware of
the study group assignments” (p. 1363)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: Several databases were searched
(blinded) for outcome data, and these data
represent a low risk of bias as missingness
will probably be evenly distributed between
groups. However, questionnaires were also
used and participants between groups may
have answered unequally because theywere
not blinded
Selective reporting (reporting bias) Unclear risk Comment: noprotocol available, so the risk
of reporting bias is unclear. The outcomes
specified in the methods were all reported
in the results
Other bias Unclear risk Received funding of diagnostic tests from
manufacturer.
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van den Broek 2012
Methods Study design: controlled trial with randomised stepped wedge implementation in 3
blocks
Setting: population-based screening in 3 regions of the Netherlands - the urban areas of
Amsterdam and Rotterdam and a defined suburban area of South Limburg (Parkstad)
Study duration: March 2008 to February 2011
Participants Young adults (women and men aged 16-29 years old, N = 317,304)
Inclusion criteria:
• Women and men aged 16-29 years old
• Listed on the municipal population register from March 2008 to February 2011
• People living in Amsterdam and Rotterdam and reporting that they ever had sex
• ’High risk’ people living in South Limburg, where chlamydia prevalence was
expected to be lower than in the cities. A risk score of ≥ 6 according to a previously
developed form was compatible with a positivity of 4-5% and excluded 20-30% of
potential participants.
• Participants providing informed consent online
Exclusion criteria:
• Aged < 16 or > 29 years old
• Moved out of area before invite sent
• Not sexually active (Amsterdam and Rotterdam)
• Low risk (South Limburg)
Interventions Enrolment: Personalised yearly invitations to be screened forC. trachomatis infection sent
to the target population through the Chlamydia Screening Implementation Programme.
The letter included the address of the programme website (www.chlamydiatest.nl) and a
secure login code through which eligible participants could request a kit for self sampling
(urine for men, vaginal swab or urine for women). Chlamydia-positive participants
automatically received a test package 6 months after the first test
Intervention group 1: invited for screening 3 times (blockA,N=55,776, 39 clusters)
Yearly chlamydia screening test offered by post 3 times. People were invited to use an
internet site to request a kit for self collected samples to be sent to laboratory for testing.
Treatment and partner notification were done via GP or STI clinic. A single reminder
letter was sent to anyone who did not access the website within 4 weeks, and email
reminders were sent to individuals who requested a kit but did not return a specimen
within 2 weeks.Test results, with a referral letter for those with positive results, were
provided online, with an email or text message reminder after 14 and 28 days and a letter
by post after 6 weeks for those who did not access it
Intervention group 2: invited for screening 2 times (block B, N = 213,497, 114
clusters)
Yearly chlamydia screening test offered by post 2 times. See intervention group 1 for
details
Control group: usual care (block C, N = 48,031, 39 clusters)
One sixth of the population were invited a single time for CT testing after the second
invitation was sent to blocks A and B
Testing for chlamydia is available from general practitioners and at sexually transmitted
infections clinics. There was no specific promotion of chlamydia testing during the trial
period
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van den Broek 2012 (Continued)
Outcomes Primary outcomes
• Prevalence of chlamydia infection (percentage of positive chlamydia test results in
those tested) in women and men combined and separately, measured at baseline (1st
invitation), 12 months (2nd invitation) and 24 months (3rd invitation)
• Prevalence of chlamydia infection (estimated chlamydia prevalence) in women
and men combined and separately, measured at baseline (1st invitation), 12 months (2
nd invitation) and 24 months (3rd invitation). Estimated prevalence of chlamydia in
whole target population was extrapolated using weighted data
• Incidence of self reported pelvic inflammatory disease in the previous 12 months
in women, measured at baseline (1st invitation), 12 months (2nd invitation) and 24
months (3rd invitation)
Secondary outcomes
• Proportion of participants receiving the intervention (= uptake of screening) in
women and men combined and separately, measured at baseline (1st invitation), 12
months (2nd invitation) and 24 months (3rd invitation). Percentage participating (the
proportion of invitees who send a sample to the laboratory)
Notes The study was approved by the Medical Ethics Committee Free University Amsterdam
(Identification number 2007/239). The Dutch organisation for Health Research and
Development (ZonMW, project number 12.400.001) funded the project. No protocol
available but details of study design are in related paper van den Broek 2010
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Quote: “The order of invitation of clus-
ters was randomised by assigning computer
generated random numbers to clusters and
then sorting clusters within one block us-
ing these numbers (using Microsoft Excel
2002)” (p. 3)
Allocation concealment (selection bias) Unclear risk Comment: The investigators were blinded
to the identity of clusters (allocated to block
= comparison groups A, B, C) and did
not know whether the intervention effect
might differ by risk level or cluster size.
The subsequent randomisation of the or-
der of implementation within blocks and
addition of a third round of screening in
block B would also reduce the risk of bias
in the results
Quotes: “Althoughwe stratified the clusters
according to community risk level, the in-
tervention and control blockwere not com-
pletely comparable in all 3 regions” (p. 5)
“The participation rate in the control block
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van den Broek 2012 (Continued)
C was not completely comparable to that
achieved after the first invitation in the in-
tervention blocks A and B” (p. 5)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Comment: no blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: no blinding of outcome assess-
ment, but the review authors judge that the
outcome measurement is not likely to be
influenced by lack of blinding
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: primary outcomes only: incom-
plete data (for positivity and thus preva-
lence) associated with intervention uptake.
For PID, very low reporting (1st invitation,
assumed to be baseline with no screening in
the previous 12 months,1072/29,831; 2nd
invitation, presumed to be 12 months af-
ter screening, 2261/20,246; 3rd invitation
2340/16,853) anddifferent proportions re-
sponding to questionnaire at each round
Reason for missing outcome data likely to
be related to true outcome
Selective reporting (reporting bias) Low risk All outcomes in study design paper re-
ported in main paper
Other bias Unclear risk Contamination; quote: “cluster allocation
could have reduced, but not eliminated,
transmission of chlamydia within clusters.
Sexual networks do not strictly follow geo-
graphical boundaries and the blocks for im-
plementation were not contiguous” (p. 5).
Not enough information to assess whether
contaminationoccurred. Lowuptake of the
intervention could reduce the size of any
difference between intervention and con-
trol groups
CT: Chlamydia trachomatis; FSW: female sex workers; GP: general practitioner; PID: pelvic inflammatory disease; STI: sexually
transmitted infection.
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
ACTRN12608000499381 RCT. CLASP trial. No eligible primary outcome: report uptake of testing and CT prevalence at 6
months only
Andrews 2006 Not an RCT. Observational study nested within RCT of pregnant women randomised to antibiotic or
no treatment for Trichomonas vaginalis or bacterial vaginosis
Bailey 2013 RCT; no eligible primary outcome; chlamydia testing at 3 months only
Banhidy 2011 RCT in pregnant women; no real difference between groups; both groups screened, report pre-term
birth for treated vs untreated and for infection with any sexually transmitted infection vs no infection
Bowden 2008 RCT; no eligible primary outcome; main outcome was chlamydia testing uptake
Brown 2010 RCT; no eligible primary outcome; routine chlamydia testing only. Outcomes were patient satisfaction,
doctor/nurse screening vs self taken sample, number of cases detected, time taken in clinic
Cabeza 2015 Feasibility study of chlamydia screening in pregnant women; no control group
Chandeying 1998 RCT; no eligible primary outcome; routine chlamydia screening only. Immediate results only; no long
term outcomes
Cohen 1999 Register-based screening cluster-CCT, repeat testing in schools 5 screening rounds vs usual care.Wrong
intervention, cluster-CCT ’control’ schools not enrolled concurrently with intervention
Cook 2007 RCT; participants not eligible. Didn’t measure prevalence, but screened women with recent sexually
transmitted infection
De Barbeyrac 2013 RCT; no eligible primary outcome; main outcome was screening rate after internet offer of home
screening vs usual care
Downing 2013 RCT; no eligible primary outcome; chlamydia retesting at 3 months only
Gotz 2013 RCT; no eligible primary outcome; chlamydia retesting at 4-5 months only after home vs clinic-based
recall
Graseck 2010 RCT; no eligible primary outcome; chlamydia retesting at 12monthswas cross-sectional, not performed
as a follow-up
Guy 2013 RCT; no eligible primary outcome; CT retesting at 3 months only
Hodgins 2002 RCT; no eligible primary outcome; ’prevalence’ at 12 months measured differently in intervention and
control after cluster-randomised mass screening
ISRCTN16261241 RCT; no eligible primary outcome; reports uptake of testing and uptake of Papanicolau smears
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(Continued)
ISRCTN38526137 RCT; no primary outcome; reports uptake of testing only
Jones 2007 RCT; no eligible primary outcome; main outcome uptake of screening at 6 weeks
Kekki 2001 RCT in pregnant women; intervention not eligible. All women screened for chlamydia, and only those
with bacterial vaginosis randomised to treatment or no treatment for bacterial vaginosis
Kersaudy-Rahib 2013 RCT; no eligible primary outcome; main outcome was uptake of screening
Kiss 2004 RCT in pregnant women; no eligible primary outcome; screening for bacterial vaginosis, Trichomonas
vaginalis and candida only, but not chlamydia
Klovstad 2013 RCT; no eligible primary outcome; study period 3 months only
Lawton 2010 RCT; pilot study only. No eligible primary outcome; main outcome was uptake of testing
Martin 1997 RCT in pregnant women; intervention not eligible
McGregor 1990 RCT in pregnant women; intervention not eligible. Treatment with erythromycin vs no treatment was
not equivalent to screen vs no screening
McGregor 1995 CCT in pregnant women; comparison not eligible: no comparison of screened vs unscreened
McKee 2011 RCT; no eligible primary outcome; main outcome uptake of chlamydia testing
Meyer 1991 RCT; no eligible primary outcome: main outcome was incidence of discharge
NCT00829517 RCT; no eligible primary outcome; report chlamydia positivity at 3 months only
NCT01654991 RCT; no eligible primary outcome; report uptake of chlamydia screening in men
Niza 2014 RCT; no eligible primary outcome; main outcome was return of screening kits
Scholes 2006 RCT; no eligible primary outcome; only reports uptake of chlamydia testing
Scholes 2007 RCT; no eligible primary outcome; chlamydia retesting at 4 months only
Senok 2005 RCT; no eligible primary outcome; only reports uptake of testing and chlamydia positivity up to 4
months
Shafer 2002 RCT; no eligible primary outcome; do not report positivity at 12 months
Smith 2014 RCT; no eligible primary outcome; chlamydia retesting at 1-4 months only
Stevens-Simon 2002 Study in pregnant teenagers; no eligible primary outcome; only measured chlamydia positivity once in
a random subset of pregnancy test urine samples; no pregnancy outcomes
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Tebb 2005 RCT; no eligible primary outcome; report chlamydia screening rate in boys
Tebb 2009 RCT; no eligible primary outcome; report chlamydia screening rate in girls
Walker 2010 RCT; no eligible primary outcome; report uptake of chlamydia testing
Xu 2011 RCT; no eligible primary outcome; chlamydia retesting at 3 months of treated women
CT: Chlamydia trachomatis; CCT: controlled clinical trial; RCT: randomised controlled trial.
Characteristics of ongoing studies [ordered by study ID]
Hocking 2010
Trial name or title ACCEPt Australian Chlamydia Control Effectiveness Pilot: A randomised controlled trial to determine
whether an intervention of annual chlamydia testing in general practice for sexually active men and women
aged 16 to 29 years can lead to a reduction in chlamydia prevalence
Methods Cluster-randomised controlled trial
Participants General practice clinics within postcode areas with a population of between 5000 to 30,000. A total of 54
postcodes (towns) will be randomised, and all general practice clinics within the postcode will be invited to
participated. All clinics will be eligible for participation
Interventions Intervention group: annual testing. GPs will be asked to screen sexually active men and women aged 16
to 29 years for chlamydia. The multifaceted intervention to maximise testing includes: a computer alert
prompting GPs to test; incentive payments for GPs and payments for employing practice nurses; a recall
system to encourage annual testing; partner notification, and information/support with regular feedback on
testing performance
Control group: usual care. Clinics in the control group are encouraged to continue their usual practice
Outcomes Primary outcome: change in chlamydia prevalence among a consecutive sample of 80-100 patients attending
participating clinics in each postcode
Secondary outcomes: incidence of pelvic inflammatory disease; chlamydia testing rates
Starting date 1 May 2010
Contact information Dr Jane Hocking, jhocking@unimelb.edu.au
Notes Trial registration number: ACTRN12610000297022
Ethical approval obtained from Ethics Committee of the Royal Australian College of General Practitioners
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Kaldor 2010
Trial name or title Sexually Transmitted Infections (STI) in Remote communities: ImproVed & Enhanced primary health care
- a randomised community trial to reduce STIs in remote Aboriginal and Torres Strait Islander communities,
comparing clinical care enhanced with a Sexual Health Quality Improvement Program with standard clinical
care
Methods Stepped wedge community cluster-randomisation
Participants Sexually active 14-34 year olds living in remote communities in Australia with a resident population of
Aboriginal or Torres Strait Islander people aged 16-34 years. A total of 68 communities were randomised
Inclusion criteria: communities considered remote by the Australian Bureau of Statistics (ABS); with a
resident population of at least 100 people of Aboriginal people, Torres Strait Islanders or both, aged 16-34
years; with community and health services willing and able to provide access to de-identified clinical data;
with health services able to sustain data collection, consistent with the trial protocol
Exclusion criteria: communities where there is a diverse range of health services within the same area that
are accessed by Aboriginal people, Torres Strait Islanders or both
Interventions Randomisation will occur over a period of 3 years. At the start of each year, 7 of the trial clusters will be
randomised to the intervention, the following year a further 7 will be randomised, and in the third year, the
final 7 will be randomised such that by the end of the trial, all clusters will have received the intervention.
For clusters that are randomised in year 1, the intervention will continue for 3 years. For clusters randomised
in year 2, the intervention will continue for 2 years. For clusters randomised in year 3, the intervention will
continue for 1 year
Intervention group: The intervention, called the Sexual Health Quality Improvement Program will involve
the following components:
1. Development of an action plan including goals and strategies to improve clinical service delivery for
diagnosis and management of bacterial STIs to reach best practice targets. STRIVE Coordinators will meet
with participating primary health services annually for a day to undertake a site assessment, develop an
Action Plan tailored to the individual service and discuss goals and strategies for the Action Plan.
2. 6-monthly collaborative feedback meetings to discuss progress on the Action Plan. STRIVE
Coordinators will meet with health service management to discuss the Action Plan and progress towards the
goals and strategies developed.
3. Quantitative data reports will be provided to health services every 6 months showing progress towards
best practice targets.
4. Training - STRIVE coordinators will provide staff with training in quality improvement and basic
research skills and encourage further training in sexual health. Training requirements will be discussed at the
collaborative feedback meetings.
5. Incentives payments based on progress towards the best practice targets. Opportunities exist for each
health service to receive a total incentive payment of between $10,000 and $30,000 per year. Incentives will
be calculated from the quantitative reports and will be paid every 6 months.
Control group: standard clinical care according to clinical guidelines which include screening, assessment,
treatment, management, prevention and reporting recommendations. Clinicians are recommended to follow
these guidelines on a case-by-case basis
Outcomes Primary outcome: Prevalence of chlamydia infection in women and men, measured annually and at the end
of the trial
Secondary outcome: Proportion of participants receiving the intervention (= uptake of screening), measured
annually and at the end of the trial
Starting date 1 September 2010
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Kaldor 2010 (Continued)
Contact information J Kaldor, jkaldor@kirby.unsw.edu.au
Notes Ethical approval obtained fromWestern Australian Aboriginal Health Information Ethics Committee; Cairns
Base Hospital Ethics Committee; Central Australian Human Research Ethics Committee; Human Research
Ethics Committee of Northern Territory Department of Health and Families and Menzies School of Health
Research; Western Australian Country Health Service Board Research Ethics Committee; University of New
South Wales Human Research Ethics Committee (B)
Lehtinen 2015
Trial name or title Characteristics of a randomised Chlamydia screening trial
Methods Community cluster-randomised trial
Participants Women born in 1992-1995 living in 44 communities in Finland (33 screened, 11 unscreened)
15,000 women invited for screening per year. The invitation contains information on C. trachomatis and
its treatment and about an FVU-sampling kit, which is available through a website (www.rokotiitus.net). A
consent form is included to be mailed/donated together with the FVU-sample
Interventions Communities will be divided into 4 groups for biannual, quadrennial or a single screening round at the end
of the study. Target number of women born 1992-1995, N = 60,000, approximately 15,000 per arm
Intervention group 1: biannual screening at the ages of 18.5, 20 and 22
Intervention group 2: biannual screening at the ages of 18.5, 20 and 22
Intervention group 3: quadrennial screening at the ages of 18.5 and 22
Control group: 11 unscreened communities (no offer of screening until age 22)
Outcomes Primary outcome: prevalence of chlamydia infection in women at age 22 (3.5 years after start of study);
ITT analysis of groups 1 + 2 vs control (screened 3 times vs screened 1 x only at end of study); prevalence of
chlamydia infection in women at age 22 (3.5 years after start of study) groups 1 + 2 vs groups 3 + control,
ITT analysis (screened 3 times vs screened 2 x or 1 x only at end of study)
Secondary outcome: proportion of participants receiving the intervention (= uptake of screening) at baseline
(other time points not reported)
Starting date Autumn 2010
Contact information M Lehtinen, University of Tampere, Finland
Notes Permission for the trial was obtained from the ethical review board of theNorthOstrobotnia Hospital District,
Oulu, Finland
Performed as part of an HPV vaccination trial.
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NCT01195220
Trial name or title Project AWARE: using the ED to prevent STIs in youth
Methods Randomised controlled trial
Participants Sexually experienced adolescents aged 14 to 21 in a large, inner-city ED in the Bronx (NY)
Estimated enrolment: 690
Interventions Intervention group 1: combined HIV/STI screening. Current standard of care with video to obtain informed
consent for rapid on-site HIV testing, with additional information in video about other STIs and added
gonorrhoea and chlamydia screening of a urine sample
Intervention group 2: combined HIV/STI screening with theory-based risk reduction video counselling. As
intervention 1 with additional behavioural video to encourage safer sex
Control group: HIV testing. Current standard of care with video to obtain informed consent for rapid on-
site HIV testing
Outcomes Primary outcomes: test positivity for chlamydia or gonorrhoea 4 months postintervention
Secondary outcomes: test positivity for chlamydia or gonorrhoea 8 months and 12 months postintervention;
intentions for condom use immediately after as well as 4, 8 and 12 months postintervention
Starting date December 2011
Contact information Dr Yvette Calderon, Jacobi Medical Center, North Bronx Healthcare Network, New York, United States,
10461
Notes Trial registration number: NCT01195220
ED: emergency department; FVU: first void urine; ITT: intention-to-treat; STI: sexually transmitted infection.
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D A T A A N D A N A L Y S E S
Comparison 1. Offer of chlamydia screening vs usual care (inactive control)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Prevalence of chlamydia
infection (positivity) measured
in the whole study population
at least 12 months after start of
screening
2 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
1.1 3rd invitation vs control 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 2nd invitation vs control 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.3 1st invitation vs control 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.4 Screening offer in high
school students
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Incidence of PID at 12 months
(intention-to-treat)
4 21080 Risk Ratio (M-H, Fixed, 95% CI) 0.68 [0.49, 0.94]
2.1 Low risk of detection bias 2 18022 Risk Ratio (M-H, Fixed, 95% CI) 0.80 [0.55, 1.17]
2.2 High risk of detection bias 2 3058 Risk Ratio (M-H, Fixed, 95% CI) 0.42 [0.22, 0.83]
3 Incidence of PID at 12 months
(per protocol analysis)
2 2749 Risk Ratio (M-H, Fixed, 95% CI) 0.62 [0.35, 1.10]
3.1 Low risk of detection bias 1 2377 Risk Ratio (M-H, Fixed, 95% CI) 0.65 [0.34, 1.24]
3.2 High risk of detection bias 1 372 Risk Ratio (M-H, Fixed, 95% CI) 0.55 [0.17, 1.80]
4 Incidence of epididymitis in
men at 12 months (intention
to screen)
1 14980 Risk Ratio (M-H, Fixed, 95% CI) 0.80 [0.45, 1.42]
5 Secondary outcomes for
reproductive tract morbidity
1 Risk Difference (M-H, Fixed, 95% CI) Totals not selected
5.1 Female infertility 1 Risk Difference (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.2 Ectopic pregnancy 1 Risk Difference (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
A D D I T I O N A L T A B L E S
Table 1. Effect of chlamydia screening interventions on chlamydia prevalence
Trial Study
popula-
tion
Baseline Follow-up, 12 months Re-
ported ef-
fect (95%
CI)
Follow-up, subsequent Re-
ported ef-
fect (95%
CI)Interven-
tion
Control Interven-
tion
Control Interven-
tion
Control
Ostergaard
2000
High
school stu-
dents,
Denmark
43/867a Not mea-
sured
13/443a 32/487 RD − 5.
5% (− 10
to 0.95%)
a
- - -
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Table 1. Effect of chlamydia screening interventions on chlamydia prevalence (Continued)
van
den Broek
2012
Gen-
eral popu-
lation,
Nether-
lands
1851/
43358
267/6223 1153/
28803
Not mea-
sured
OR 0.
93 (0.81 to
1.07)b
981/
23899
Not mea-
sured
OR 0.
96 (0.83 to
1.10)b
Garcia
2012
Female sex
workers,
Peru
13.8% 15.5% - - - 9.9% 14.5% RR 0.
66 (0.47 to
0.94)c
CI: confidence interval; OR: odds ratio; RD: risk difference; RR: risk ratio.
aNumbers of infections and people are the numbers reported by the authors. Risk difference, as reported by authors (difference in
mean incidence proportions across clusters). Confidence intervals for the difference did not take into account clustering.
bComparison is between intervention group at follow-up and control group at baseline. Confidence intervals do not take into account
intraclass correlation because, in a hierarchical multivariable model, clustering did not affect the results.
cTotal participants at baseline in 2002, 4130; total participants at follow-up in 2006, 4156; RR adjusted for 2002 prevalence but not
for pairing of cities.
Table 2. Uptake of chlamydia screening
Trial Eligibil-
ity (ratio interven-
tion: control)
Group Uptake in inter-
vention
Uptake in control Comment
Andersen 2011 Selected at random
from register (1:4)
Intervention: in-
vited for home-sam-
pling. Assessed after
3 months
Con-
trol: not contacted.
Tests at GP and STI
clinics assessed after
3 months
Women 4000 invited;
1175 (29.4%) sent
home-sample
11,459 not invited;
1076 (9.4%) oppor-
tunistic tests
Control group not
aware of trial. As-
sume
routine health-seek-
ing behaviour over
3 months. If control
group testing be-
haviour continued
at the same level
over 12 months, the
proportion tested by
the time the out-
come PID was mea-
sured could have
been higher
Men 5000 invited;
1033 (20.7%) sent
home-sample
9980 not invited;
140 (1.4%) oppor-
tunistic tests
Garcia 2012 Sex
work venues identi-
fied and visited by
mobile teams
Women Could not be calcu-
lated
Could not be calcu-
lated
Not designed to
measure uptake; no
denominator
Oakeshott 2010 Approached in col-
leges;
all women enrolled
Women 1259 (100%) im-
mediate screening;
1270 (100%) de-
ferred screening;
Not designed to
measure uptake
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Table 2. Uptake of chlamydia screening (Continued)
were tested, ran-
domised (1:1)
269 (21%) oppor-
tunistic tests
258 (20%) oppor-
tunistic tests
Ostergaard 2000 Schools randomised
(1:1)
Intervention: allo-
cated to home-sam-
pling
Control:
allocated to offer of
GP testing
Sexually ac-
tive respondents eli-
gible. Assessed after
4 months
Women 2603 allocated;
928 eligible respon-
ders;
867 (93.4%) sent
home-sample
2884 allocated;
833 eligible respon-
ders; 63 (7.6%) op-
portunistic tests
All stu-
dents in school were
allocated to inter-
vention or control
groups and asked
if they would take
part. Of the respon-
ders, only those who
had ever had sex
were eligible. The
denominator of of
all who had ever had
sex was not known
Inter-
vention group given
home-sampling kits
Men 1733 allocated;
442 eligible respon-
ders;
430 (97.3%) sent
home sample
1689 allocated;
246 eligible respon-
ders;
4 (1.6%)
opportunistic tests
-
Scholes 1996 Individuals
randomised (1:2)
Respondents fulfill-
ing criteria for high
risk of chlamydia el-
igible
Women 36,457 randomised; 20,836 responded;
3111 at high risk
Numbers al-
located to interven-
tion and control not
reported. Interven-
tion group actively
contacted
1009 invited
645 (64%) tested
1598 not invited;
% tested not known
van den Broek 2012 Postal areas
allocated (5:1)
Intervention: allo-
cated to yearly invi-
tation x3
Control: allocated
to single invitation
Women
1st
2nd
3rd
142,419 invited;
29,831 (21.3%)
tested
141,078 invited;
20,246 (14.7%)
tested
131,010 invited;
16,853 (17.4%)
tested
24,172 invited;
4199 (17.4%)
tested
Postal invi-
tation contained se-
cure login code. Re-
cipients had to reg-
ister on website to
request home-sam-
pling kit. One re-
minder letter
Men
1st
2nd
3rd
129,462 invited;
13,617 (10.5%)
tested
128,299 invited;
8,616 (6.7%) tested
121,156 invited;
23,884 invited
2025 (8.5%) tested
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Table 2. Uptake of chlamydia screening (Continued)
6,970 (5.6%) tested
All
1st
2nd
3rd
269,273 invited;
43,358 (16.2%)
tested
265,979 invited;
28,803 (10.8%)
tested
251,688 invited;
23,899 (9.5%)
tested
48,031 invited
6,223 (13.0%)
tested
GP: general practitioner; PID: pelvic inflammatory disease; STI: sexually transmitted infection.
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Types of outcome measures: there is an error in a part of the text of the protocol, but the outcomes stated under the headings ’Primary
outcomes’ and ’Secondary outcomes’ in the protocol are correct and are the same as those reported in the review. The statement
following the list of secondary outcomes, “The following outcome will not be included: uptake of chlamydia screening . . .” should
read, “The following outcome will not be included as a primary outcome: uptake of chlamydia screening.”
We did not calculate the number needed to treat for an additional beneficial outcome (NNTB) or the number needed to treat for an
additional harmful outcome (NNTH).
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